

**A Phase 2, Proof-of-Concept, Randomized, Double-Blinded,  
Placebo-Controlled Study of ACH-0144471 Treatment for 6  
Months in Patients with C3 Glomerulopathy (C3G), with an  
Open-Label Extension**

<b>Unique Protocol ID:</b>	ACH471-204
<b>NCT Number:</b>	NCT03369236
<b>EudraCT Number:</b>	2017-000663-33
<b>Date of Protocol:</b>	15 May 2020

# CLINICAL TRIAL PROTOCOL

## ACH471-204

**Study Title:** A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G), with an Open-Label Extension

**Study Number:** ACH471-204

**Study Phase:** 2

**Product Name:** ACH-0144471 Tablets

**Regulatory Agency and Registry Identification Numbers:** IND: 129,916  
EudraCT: 2017-000663-33  
ClinicalTrials.gov: NCT03369236  
WHO UTN: U1111-1203-9076

**Indication:** C3 Glomerulopathy (C3G)

**Investigators:**

**Sponsor:** Achillion Pharmaceuticals, Inc. (a subsidiary of Alexion Pharmaceuticals, Inc.)

**Medical Monitor:** PPD [REDACTED]  
Direct PPD [REDACTED] Mobile PPD [REDACTED]

	Date
<b>Original Protocol:</b>	25 August 2017 (Version 1.0)
<b>Amendment 1:</b>	25 October 2017 (Version 2.0)
<b>Amendment 2:</b>	12 December 2017 (Version 3.0)
<b>Amendment 3:</b>	07 March 2018 (Version 4.0)
<b>Amendment 4:</b>	02 November 2018 (Version 5.0)
<b>Amendment 5:</b>	15 February 2019 (Version 6.0)
<b>Amendment 6:</b>	19 June 2019 (Version 7.0)
<b>Amendment 7:</b>	15 May 2020 (Version 8.0)

### Confidentiality Statement

The information contained in this document, particularly unpublished data, is the property or under the control of Achillion Pharmaceuticals, Inc. (a subsidiary of Alexion Pharmaceuticals, Inc.), and is provided to you in confidence as an investigator, potential investigator, or consultant for review by you, your staff and an applicable Institutional Review Board and/or Independent Ethics Committee. The information is only to be used by you and in connection with authorized clinical studies of the investigational drug described in the protocol. You will not disclose any of the information to others without written authorization from Achillion Pharmaceuticals, except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered.

**SPONSOR SIGNATURE(S)**

**Study Title:** A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G), with an Open-Label Extension

**Study Number:** ACH471-204

**Protocol Version and Date** 15 May 2020 (Version 8.0)

This clinical study protocol has been approved by the sponsor.

PPD

PPD

Date

Alexion Pharmaceuticals, Inc.  
121 Seaport Blvd  
Boston, MA 02210

PPD

22-May-2020 | 12:35:15 EDT

**INVESTIGATOR'S SIGNATURE(S)**

**Study Title:** A Phase 2, Proof-of-Concept, Randomized, Double-Blinded,  
Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months  
in Patients with C3 Glomerulopathy (C3G), with an Open-Label  
Extension

**Study Number:** ACH471-204

**Protocol Version and Date** 15 May 2020 (Version 8.0)

I have read the protocol described above. I agree to comply with all applicable regulations and to conduct the study as described in the protocol.

---

<Name and Credentials/Title>

---

Date

<Affiliation/Company>

<Address>

<Address>

<Phone Number>

**SYNOPSIS**

<b>Sponsor</b>	Achillion Pharmaceuticals, Inc. (a subsidiary of Alexion Pharmaceuticals, Inc.) 121 Seaport Blvd Boston, MA 02210 Phone: PPD
<b>Name of Finished Product</b>	ACH-0144471 Tablet: 50 and 100 mg Placebo for ACH-0144471 Tablet: 50, and 100 mg
<b>Name of Active Ingredient</b>	ACH-0144471
<b>Name of Inactive Ingredient</b>	ACH-0144471 Tablet: Lactose, Microcrystalline Cellulose, Croscarmellose Sodium, Sodium Lauryl Sulphate, Magnesium Stearate, Colloidal Silicon Dioxide, and Hypromellose Acetate Succinate. The coating components are: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, and talc Placebo Tablet: Lactose, Microcrystalline Cellulose, Croscarmellose Sodium, Sodium Lauryl Sulphate, Magnesium Stearate, Colloidal Silicon Dioxide, and Hypromellose Acetate Succinate. The coating components are: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, and talc
<b>Study Title</b>	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G), with an Open-Label Extension
<b>Study Number</b>	ACH471-204
<b>Study Phase</b>	Phase 2
<b>Primary Objective</b>	<ul style="list-style-type: none"> <li>To evaluate the efficacy, relative to placebo, of 6 months of oral ACH-0144471 in participants with C3G based on histologic scoring and proteinuria</li> </ul>
<b>Secondary Objectives</b>	<ul style="list-style-type: none"> <li>To evaluate the clinical effect, relative to placebo, of 6 months of oral ACH-0144471 in participants with C3G based on improvement in slope of estimated glomerular filtration rate (eGFR) relative to baseline over time</li> <li>To evaluate for improvement in eGFR following treatment with ACH-0144471, relative to placebo</li> <li>Where available, evaluate the change in measured (m) GFR relative to baseline at end of 6 months study drug treatment</li> <li>To evaluate the safety and tolerability of ACH-0144471 in participants with C3G by assessing serious adverse events (SAEs)</li> </ul>
<b>Study Design</b>	This is a randomized, placebo-controlled, double-blinded study with 6 months of dosing, followed by a 6-month open-label extended treatment period and up to an additional 21 months long-term follow-up period. The study will include approximately 20 subjects. Participants enrolled will be randomized 1:1 to ACH-0144471 or placebo, stratified by the disease diagnosis (dense deposit disease [DDD] or C3 glomerulonephritis [C3GN]) and renal function at study entry (eGFR $\geq 60$ mL/min/1.73 m <sup>2</sup> or $< 60$ mL/min/1.73 m <sup>2</sup> ). For all participants, eligibility will be confirmed based on the results from screening eligibility assessments. Once eligibility is confirmed, arrangements can be made for a renal biopsy and/or vaccination, as discussed below.

	<p>The initial screening visit must occur no more than 75 days before the first dose date.</p> <p>All participants should be vaccinated against <i>Haemophilus influenzae</i> (<i>H. influenzae</i>), <i>Streptococcus pneumoniae</i> (<i>S. pneumoniae</i>), and <i>Neisseria meningitidis</i> (<i>N. meningitidis</i>) to minimize the risk of serious infection with an encapsulated organism. Vaccinations should be administered at least 2 weeks before the start of dosing with ACH-014447 according to Advisory Committee on Immunization Practices (ACIP) guidelines, as described in Section 6.4, unless otherwise recommended by national and/or local vaccination guidelines or precluded by licenses or availability. The PI may institute additional prophylactic measures, including the use of prophylactic antibiotics, if deemed appropriate by local clinical practice and/or guidelines for treatment with a complement inhibitor.</p> <p>The starting dosage of ACH-0144471 will be 100 mg three times daily (TID), a total daily dose of 300 mg. After 2 weeks of treatment, dosing will be escalated to 200 mg TID. Additional dosage regimens may be investigated if supported by emerging data from this and other clinical studies. Upon treatment discontinuation, regardless of the timing or reasons for discontinuation, a 6-day taper period is required unless the PI determines this taper period poses a risk to the participant. The taper period is in place to prevent the theoretical risk of marked increase or rebound in complement activity, as described in Section 5.2.1.</p> <p>Because C3G is a serious and chronic disease, this study includes an extended treatment period. All participants entering the Extended Treatment Period will receive ACH-0144471; those on active treatment will continue to receive daily treatment with ACH-0144471 and safety and efficacy monitoring, while those on placebo treatment will transition to active treatment with appropriate safety and efficacy monitoring.</p>
<b>Study Visit Schedule</b>	<p>On Day 1, the required pre-dose assessments will be obtained, followed by administration of the first dose of study drug. Additional outpatient clinic visits will occur as described in the Schedule of Assessments (<a href="#">Appendix 1</a>) for the rest of the Blinded Treatment Period (to Week 28).</p> <p>At each visit, safety and efficacy will be assessed. Safety assessments may include physical examination, vital signs, electrocardiogram (ECG) measurements, and safety laboratory testing. Samples will be collected for measurement of complement biomarkers at selected visits as specified in the Schedule of Assessments (<a href="#">Appendix 1</a>). Quality of Life and Patient Reported Outcomes assessments will occur according to the Schedule of Assessments (<a href="#">Appendix 1</a>).</p> <p>Upon completion of the Blinded Treatment Period, participants may continue in the open-label Extended Treatment Period in which all participants will receive active treatment.</p> <p>The 6-month Open Label Extension will end at Week 52, participants may continue to the Long-Term Follow-up period for up to an additional 21 months. Participants will continue on ACH-0144471 until up to Week 143.</p> <p>At the end of treatment, a 6-day taper will occur to allow gradual return of complement activity to baseline. If a participant discontinues from the study early, study participation</p>

	is not necessarily immediately terminated. Instead, whenever possible, dosing of ACH-0144471 should be tapered over 6 days. Whether dosing is tapered or not, all participants should return for two follow-up visits, 2 and 4 weeks after the last dose of study drug
<b>Treatment Groups:</b>	There will be two treatment groups, with participants randomized 1:1 to either active treatment with ACH-0144471 or to placebo, stratified by disease diagnosis (DDD or C3GN) and renal function at study entry (eGFR $\geq 60$ mL/min/1.73 m <sup>2</sup> or $< 60$ mL/min/1.73 m <sup>2</sup> ).
<b>Study Population</b>	Participants must have biopsy-confirmed DDD or C3GN, have not undergone renal transplant, and have significant proteinuria
<b>Number of Participants</b>	20
<b>Inclusion Criteria</b>	<p>Each participant must meet all of the following criteria to be enrolled in this study:</p> <ol style="list-style-type: none"> <li>1. Must have biopsy-confirmed primary C3G</li> <li>2. Must be 17 years of age or older and capable of swallowing tablets</li> <li>3. Must have clinical evidence of ongoing disease based on significant proteinuria (defined as <math>\geq 500</math> mg/day of protein in a 24-hour urine or equivalent on spot urine) attributable to C3G disease in the opinion of the PI, and present prior to study entry and confirmed during Screening</li> <li>4. If on corticosteroids, anti-hypertensive medications, anti-proteinuric medications (e.g., ACE inhibitors or angiotensin receptor blockers [ARBs]), or mycophenolate mofetil (MMF), must be on a stable dose for at least 2 weeks prior to screening</li> <li>5. Female participants of childbearing potential must agree to use an acceptable method of contraception (as defined in Section 5.5.4) from the date of signing the informed consent to the first day of dosing (Day 1), and must agree to use a highly effective form of contraception (as defined in Section 5.5.4) from the first day of dosing to 30 days after their last dose of study drug. Female participants of childbearing potential must also have a negative serum pregnancy test during Screening and negative urine pregnancy test on Day 1. Female participants of non-childbearing potential need not employ a method of contraception</li> <li>6. Non-sterile male participants must agree to use a highly effective form of contraception (as defined in Section 5.5.4) with their partner(s) of childbearing potential from the first day of dosing to 90 days after their last dose of study drug.  Male participants who are surgically sterile need not employ additional contraception.  Male participants must agree not to donate sperm while enrolled in this study and for 90 days after their last dose of study drug.</li> <li>7. Adult participants must be capable of providing written informed consent and adolescent participants must be capable of providing written assent. All participants must be willing and able to comply with the requirements and restrictions listed in the consent form and with all procedures in the protocol, including, the visit schedule, the treatment plan, the schedule for laboratory testing, and other study procedures</li> </ol>

	<ol style="list-style-type: none"> <li>8. Must be up-to-date on routine vaccinations, or willing to be brought up-to-date, based on local guidelines</li> <li>9. Must have access to emergency medical care</li> </ol>
<b>Exclusion Criteria</b>	<p>Participants who meet any of the following criteria will be excluded from the study.</p> <ol style="list-style-type: none"> <li>1. Have a history or presence of any clinically relevant co-morbidities that would make the participant inappropriate for the study (for example, a comorbidity which is likely to result in deterioration of the participant's condition, affect the participant's safety during the study, or confound the results of the study), in the opinion of the PI</li> <li>2. Have ever received ACH-0144471</li> <li>3. Have a pre-treatment renal biopsy, or a recent historical biopsy available for review, which shows more than 50% global fibrosis or more than 50% of glomeruli with cellular crescents</li> <li>4. Have an estimated GFR <math>&lt;30</math> mL/min/1.73 m<sup>2</sup> at the time of screening or at any time over the preceding four weeks</li> <li>5. Is a renal transplant recipient or receiving renal replacement therapy</li> <li>6. Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant</li> <li>7. Have evidence of monoclonal gammopathy of unclear significance (MGUS), infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary</li> <li>8. Have other renal diseases that would interfere with interpretation of the study</li> <li>9. Have been diagnosed with or show evidence of hepatobiliary cholestasis</li> <li>10. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration</li> <li>11. Have a history of febrile illness, a body temperature <math>&gt;38^{\circ}\text{C}</math>, or other evidence of a clinically significant active infection, within 14 days prior to study drug administration</li> <li>12. Have evidence of human immunodeficiency virus (HIV), hepatitis B infection, or active hepatitis C infection at Screening</li> <li>13. Have a history of meningococcal infection within the prior year</li> <li>14. Have a history of hypersensitivity reactions to commonly used antibacterial agents, including beta-lactams, penicillin, aminopenicillins, fluoroquinolones, cephalosporins, and carbapenems, which, in the opinion of the investigator and/or an appropriately qualified immunology or infectious disease expert, would make it difficult to properly provide either empiric antibiotic therapy or treat an active infection.</li> <li>15. Have participated in a clinical study in which an investigational drug was given within 30 days, or within 5 half-lives of the investigational drug, whichever is longer, prior to the first dose of study drug</li> <li>16. Have received eculizumab at any dose or interval within the past 50 days prior to the first dose of study drug</li> <li>17. Have received tacrolimus or cyclosporine within 2 weeks of the first dose of study drug</li> </ol>



	<p>18. Have any of the following laboratory abnormalities at screening:</p> <ul style="list-style-type: none"> <li>Alanine transaminase (ALT) &gt; upper limit of normal (ULN)</li> <li>Aspartate aminotransferase (AST) &gt; ULN</li> <li>Absolute neutrophil counts (ANC) &lt;1,000/<math>\mu</math>L</li> <li>Total bilirubin &gt;1.5<math>\times</math> ULN</li> <li>Indirect bilirubin &gt; ULN</li> <li>Any laboratory abnormality that, in the opinion of the PI, would make the participant inappropriate for the study</li> </ul> <p>19. Are unwilling or unable to comply with the study protocol for any reason</p>
<b>Stopping Rules for Individual Participants</b>	<p>Any individual participant who meets any of the following criteria may be discontinued from further dosing:</p> <ul style="list-style-type: none"> <li>The participant experiences a SUSAR</li> <li>The PI believes that participant continuation in the study is not advisable, or the participant withdraws from the study or meets one of the conditions described in Section 6.21, including, but not limited to: <ul style="list-style-type: none"> <li>The participant becomes pregnant</li> <li>Intercurrent illness that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree</li> <li>Participant requests to discontinue for any reason</li> </ul> </li> </ul> <p>Discontinuation of treatment should also be considered if:</p> <ul style="list-style-type: none"> <li>ALT or AST &gt;8<math>\times</math> ULN</li> <li>ALT or AST &gt;5<math>\times</math> ULN for more than 2 weeks</li> <li>ALT or AST &gt;3<math>\times</math> ULN and concomitant total bilirubin &gt;2<math>\times</math> ULN and/or International Normalized Ratio [INR]* &gt;1.5</li> <li>ALT or AST &gt;3<math>\times</math> ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (&gt;5%)</li> <li>If there is a marked prolongation of the QT/QTc interval during treatment with the study drug, especially if the measurement is obtained from more than one ECG</li> </ul> <p>* Participants, particularly those with nephrotic syndrome, may be receiving ongoing warfarin, resulting in increased INR values. The PI should evaluate INR in the context of any concomitant medications to determine if any observed increases are due to an effect on liver function or are secondary to anticoagulation.</p> <p>Upon dosing termination, a participant will be expected to complete the study, if possible, by complying with the schedule for the Taper Period (if relevant) and Follow Up Period. Of note, additional visits beyond those specified in the protocol may be required if needed to ensure adequate safety monitoring.</p>

<b>Duration of Treatment, Confinement, and Total Study Participation</b>	Screening is up to 75 days. Treatment in the Blinded Treatment Period is 6 months with an additional 6 months of open-label treatment period and up to a 21-month long-term extension. The study is up to 33 months long, and follow-up may be an additional 28 days if not going into an extension study. Therefore, a participant's participation will up to 37 months.
<b>Safety Assessments:</b>	Safety assessments will include assessment of AEs, clinical laboratory tests, physical examination findings, vital signs measurements, and 12-lead ECG recordings at screening, baseline, and at various time points during the study as listed in the schedule of assessments ( <a href="#">Appendix 1</a> ).
<b>Pharmacodynamic and Efficacy Assessments</b>	Pharmacodynamics will be evaluated using serum, plasma, and/or urine collected at the time points listed in the Schedule of Assessments ( <a href="#">Appendix 1</a> ).  Samples will be collected and retained for non-genetic complement-associated biomarker testing.
<b>Patient-Reported Outcomes Assessments</b>	Patient-reported outcome (PRO) questionnaires will be administered at various time points as specified in the Schedule of Assessments in <a href="#">Appendix 1</a> , to assess participants' health-related quality of life, fatigue, and kidney-related symptoms, and to determine health states value over the course of treatment with ACH-0144471/placebo. The questionnaires are:  Adult participants: <ul style="list-style-type: none"> <li>• KDQOL-SF v1.3 questionnaire</li> <li>• FACIT-Fatigue scale version 4.0</li> <li>• EQ-5D-3L questionnaire</li> </ul>
<b>Statistical Methods:</b>	Primary efficacy endpoints: <ul style="list-style-type: none"> <li>• Change from baseline in biopsy, based on a score incorporating changes in both the activity index and C3 staining, at the end of 6 months of treatment</li> <li>• Number and percent of participants with reduction in proteinuria relative to baseline at the end of 6 months of treatment</li> </ul> Secondary efficacy endpoints: <ul style="list-style-type: none"> <li>• Change and percent change from baseline in proteinuria over the 6 months of treatment</li> <li>• Change and percent change from baseline in eGFR over the 6 months of treatment</li> <li>• Number and percent of patients with significant improvement relative to baseline in eGFR at the end of 6 months of treatment</li> <li>• Descriptive analysis of slope of GFR from baseline to 6 months</li> <li>• Descriptive analysis of slope of GFR after 12 months of ACH-0144471 therapy</li> </ul>

## TABLE OF CONTENTS

SPONSOR SIGNATURE(S) .....	2
INVESTIGATOR'S SIGNATURE(S) .....	3
SYNOPSIS .....	4
TABLE OF CONTENTS.....	10
LIST OF TABLES .....	14
LIST OF FIGURES .....	15
LIST OF APPENDICES .....	15
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.....	16
1. INTRODUCTION .....	19
1.1. Previous Experience with ACH-0144471 .....	19
1.2. Background.....	19
1.2.1. Complement Factor D.....	19
1.2.2. C3 Glomerulopathy .....	20
2. STUDY OBJECTIVES .....	22
2.1. Primary Objective.....	22
2.2. Secondary Objectives .....	22
2.3. Exploratory Objectives .....	22
2.3.1. Quality of Life Objectives .....	22
3. INVESTIGATIONAL PLAN.....	23
3.1. Overall Study Design and Plan.....	23
3.2. Rationale for Study Design.....	24
3.2.1. Justification of Design .....	24
3.2.1.1. Participant Population.....	25
3.2.1.2. Endpoints .....	25
3.2.1.3. Duration of Treatment .....	27
3.2.1.4. Safety Monitoring Plan.....	28
3.2.2. Justification of Dose .....	29
3.2.3. Stopping Criteria and End-of-Study Definition.....	29
3.2.3.1. Study Stopping Rules .....	29
3.2.3.2. Stopping Rules for Individual Participants.....	29
4. STUDY POPULATION SELECTION .....	31

4.1.	Study Population.....	31
4.2.	Inclusion Criteria .....	31
4.3.	Exclusion Criteria .....	32
5.	STUDY TREATMENT(S).....	34
5.1.	Description of Treatment(s).....	34
5.1.1.	Study Drug.....	34
5.1.2.	ACH-0144471.....	34
5.1.3.	Placebo.....	34
5.2.	Treatment(s) Administered.....	34
5.2.1.	ACH-0144471 or Placebo.....	34
5.2.2.	Vaccines.....	35
5.2.3.	Prophylactic Antibiotics .....	35
5.3.	Selection of Timing and Dose for Each Participant .....	35
5.3.1.	Clinic Visit Dose Administration Instructions .....	35
5.3.2.	Home Dose Administration Instructions .....	36
5.3.3.	Dose Adjustment .....	36
5.4.	Method of Assigning Participants to Treatment Groups .....	36
5.5.	Restrictions .....	37
5.5.1.	Prior and Concomitant Therapy.....	37
5.5.2.	Fluid and Food Intake.....	38
5.5.3.	Participant Activity and Other Restrictions.....	38
5.5.4.	Contraception.....	38
5.5.4.1.	Contraception for Male Participants.....	38
5.5.4.2.	Contraception for Female Participants .....	39
5.6.	Treatment Compliance.....	40
5.7.	Packaging and Labeling.....	40
5.8.	Storage and Accountability.....	41
5.9.	Investigational Product Retention at Study Site .....	41
6.	STUDY PROCEDURES .....	42
6.1.	Informed Consent .....	42
6.2.	Medical History .....	42
6.3.	Percutaneous Renal Biopsy .....	42

6.3.1.	Renal Biopsy.....	43
6.4.	Vaccination.....	43
6.5.	Prophylactic Antibiotics .....	43
6.6.	Urine Collection.....	44
6.6.1.	24-Hour Urine Collection.....	44
6.6.2.	First Morning Urine Collection .....	44
6.7.	Physical Examination .....	44
6.8.	Vital Signs .....	45
6.9.	Body Temperature .....	45
6.10.	Electrocardiography.....	46
6.11.	Clinical Laboratory Tests .....	46
6.12.	Pregnancy Testing .....	48
6.13.	Sample Collection, Storage, and Shipping .....	48
6.13.1.	Blood and Urine Collection for Complement Assays .....	48
6.13.2.	Blood Collection for Genetic Complement-Associated Biomarker Testing .....	49
6.13.3.	Blood Volumes .....	49
6.14.	Dispensing Study Drug.....	50
6.15.	Safety Assessments.....	50
6.16.	Pharmacodynamic Assessments .....	50
6.17.	Patient-Reported Outcomes Assessments.....	51
6.17.1.	Quality of Life Questionnaires .....	51
6.18.	Adverse Events Assessments.....	51
6.18.1.	Definitions .....	51
6.18.2.	Criteria for Assessing Seriousness.....	53
6.18.3.	Documentation and Reporting of Adverse Events .....	53
6.18.4.	Treatment and Follow-Up of Adverse Events .....	54
6.18.5.	Timeframe for Collection of Adverse Events.....	54
6.18.6.	Severity and Grading of Adverse Events.....	54
6.18.7.	Assessment of Causality .....	55
6.18.8.	Pregnancy .....	55
6.18.9.	Reporting Serious Adverse Events .....	56
6.18.10.	Investigator Reporting Requirements for SAEs .....	57

6.19.	Concomitant Medication Assessments .....	57
6.20.	Monitoring Participant Safety.....	57
6.21.	Removal of Participants from the Trial or Study Drug .....	57
6.22.	Study Assessments When Clinic Visits are Not Possible due to the COVID-19 Pandemic.....	58
6.23.	Study Drug Compliance and Supply When Clinic Visits are Not Possible .....	59
6.24.	Renal Biopsies When Clinic Visits are Not Possible .....	59
7.	STUDY ACTIVITIES .....	60
7.1.	Screening Period (Days –75 to -1).....	60
7.1.1.	Screening and Pre-Treatment Renal Biopsy .....	60
7.1.2.	Vaccination .....	61
7.2.	Blinded Treatment Period.....	61
7.3.	Extended Treatment Period .....	61
7.4.	21- Month Long-Term Follow-up .....	62
7.5.	Taper Period.....	62
7.6.	Follow-Up Period .....	63
7.7.	Early Termination from the Study .....	63
7.8.	Unscheduled Visits .....	63
8.	QUALITY CONTROL AND ASSURANCE .....	64
8.1.	Routine Monitoring .....	64
8.2.	Site Audits .....	64
9.	PLANNED STATISTICAL METHODS .....	65
9.1.	General Considerations.....	65
9.2.	Determination of Sample Size .....	65
9.3.	Analysis Populations .....	65
9.4.	Demographics and Baseline Characteristics.....	65
9.5.	Efficacy, including Pharmacodynamics Analysis .....	66
9.6.	Safety Analysis .....	67
10.	ADMINISTRATIVE CONSIDERATIONS .....	68
10.1.	Investigators and Study Administrative Structure .....	68
10.2.	Institutional Review Board (IRB) or Independent Ethics Committee (IEC) and Regulatory Approval.....	68
10.2.1.	Ethical Approval.....	68

10.2.2.	Regulatory Approval .....	68
10.2.3.	Amendments .....	68
10.3.	Ethical Conduct of the Study .....	68
10.4.	Participant Information and Consent .....	69
10.5.	Participant Confidentiality .....	69
10.6.	Study Monitoring .....	69
10.6.1.	Access to Information for Monitoring .....	69
10.6.2.	Access to Information for Auditing or Inspections .....	69
10.7.	Case Report Forms and Study Records .....	70
10.7.1.	Recording of Data .....	70
10.7.2.	Source Documentation and Medical/Study Records .....	70
10.8.	Protocol Deviations .....	70
10.9.	Access to Source Documentation .....	70
10.10.	Data Generation and Analysis .....	71
10.11.	Retention of Data .....	71
10.12.	Study and Site Closure .....	71
10.13.	Final Report, Publication and Disclosure Policy .....	72
11.	REFERENCES .....	73
12.	APPENDICES .....	76

## LIST OF TABLES

Table 1.	ACH-0144471 Taper Schedule .....	35
Table 2.	Clinical Laboratory Tests .....	47
Table 3.	Approximate Total Blood Volumes .....	50
Table 4.	Schedule of Assessments – Screening through Week 8 .....	76
Table 5.	Schedule of Assessments – Week 10 through Week 28 .....	79
Table 6.	Schedule of Assessments – Extended Treatment Period .....	81
Table 7.	Schedule of Assessments – 21 Month Long-Term Follow-up, with Taper and Follow-up .....	83

## LIST OF FIGURES

Figure 1.	Study Schematic.....	24
-----------	----------------------	----

## LIST OF APPENDICES

Appendix 1.	Schedule of Assessments .....	76
Appendix 2.	Fever Management Plan .....	85



**LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS**

<b>Abbreviation</b>	<b>Definition</b>
Ab	Antibody
ACE	Angiotensin converting enzyme
AE	Adverse event
ALP	Alkaline phosphatase
ALT	Alanine transaminase
ANC	Absolute neutrophil count
AP	Alternative Pathway (of complement)
ARBs	Angiotensin receptor blockers
AST	Aspartate aminotransferase
AUC	Area under the curve
BA	Bioavailability
Ba	Ba fragment of complement factor B
Bb	Bb fragment of complement factor B
BID	“bis in die” or twice daily
BMI	Body mass index
BP	Blood pressure
°C	Degrees Celsius
C3	C3 complement protein
C3a	Complement cleavage fraction of C3
C4	C4 complement protein
C5	C5 complement protein
C5a	Complement cleavage fraction of C5
C6	C6 complement protein
CFHR-5	Complement Factor H Related – 5 gene
C3G	C3 glomerulopathy
C3GN	C3 glomerulonephritis
CFU	Colony-forming unit
CKD	Chronic kidney disease
CKD-EPI	Chronic kidney disease - Epidemiology collaboration
C <sub>max</sub>	Maximum plasma concentration
CP	Classical pathway (of complement)
CRF	Case report form
CT	Computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
CYP	Cytochrome P450
DDD	Dense deposit disease
DDI	Drug-drug interaction
EC	Ethics Committee
ECG	Electrocardiogram
eCRF	Electronic case report form
eGFR	Estimated glomerular filtration rate
ELISA	Enzyme-linked immunosorbent assay

<b>Abbreviation</b>	<b>Definition</b>
EM	Electron microscopy
EQ-5D-3L	Three-level version of EuroQol 5 Dimensions questionnaire
ESRD	End stage renal disease
FACIT-Fatigue	Functional Assessment of Chronic Illness Therapy-Fatigue scale version 4.0
fB	(Complement) Factor B
fD	(Complement) Factor D
FDA	Food and Drug Administration
fH	(Complement) Factor H
fI	(Complement) Factor I
FSH	Follicle stimulating hormone
GCP	Good Clinical Practice
HbsAg	Hepatitis B surface antigen
Hct	Hematocrit
HCV	Hepatitis C virus
Hgb	Hemoglobin
H&E	Hematoxylin & eosin stain
HIPAA	Health Insurance Portability and Accountability Act of 1996
HIV	Human immunodeficiency virus
HRQOL	Health-related quality of life
HR	Heart rate
iC3b	Complement cleavage fragment of C3b
IC-MPGN	Immune-Complex Membranoproliferative Glomerulonephritis
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
INR	International normalized ratio
IRB	Institutional review board
IUD	Intrauterine device
IUS	Intrauterine hormone-releasing system
kDa	Kilodalton
KDQOL-SF	Kidney Disease Quality of Life short form questionnaire version 1.3
v1.3	
LFC	Liquid filled capsule
LLN	Lower limit of normal
LP	Lectin pathway (of complement)
MAD	Multiple-ascending dose
MCP	Membrane Co-Factor Protein
MDRD	Modification of Diet in Renal Disease
MedDRA	Medical Dictionary for Regulatory Activities
MenB	Meningococcal B
MGUS	Monoclonal gammopathy of unclear significance
MM	Medical monitor
MMF	Mycophenolate mofetil
MPA	Mycophenolic acid
msec	Millisecond

<b>Abbreviation</b>	<b>Definition</b>
NIH	National Institute of Health (US)
NOAEL	No observed adverse effect level
PAS	Periodic acid-Schiff
PD	Pharmacodynamic(s)
PI	Principal investigator
PK	Pharmacokinetic(s)
POC	Proof of Concept
PR interval	Period that extends from the beginning of the P wave until the beginning of the QRS complex
PRO	Patient-reported outcome
PT	Prothrombin time
PTT	Partial thromboplastin time
QRS	Group of electrocardiogram waves comprising the Q, R, and S waves
QT	Period (in milliseconds) from the beginning of the QRS complex until the end of the T wave
QTcF	QT interval Fridericia Correction Formula
RBC	Red blood cells
Relative BA	Relative bioavailability study
RR	Respiration rate
SAD	Single-ascending dose
SAE	Serious adverse event
SAP	Statistical Analysis Plan
sC5b-9	Soluble terminal complement complex
SD	Standard deviation
SLE	Systemic lupus erythematosus
SUSAR	Serious, unexpected suspected adverse reaction
TEAE	Treatment-emergent adverse event
THBD	Thrombomodulin
t <sub>max</sub>	Time after administration of a drug when the maximum plasma concentration is reached
UGT	UDP-glucuronosyltransferase
ULN	Upper limit of normal
WBC	White blood cells
Wk	Week

## 1. INTRODUCTION

ACH-0144471, a small molecule, orally administered, factor D (fD) inhibitor, is in development by Achillion Pharmaceuticals, Inc. (“Achillion”, or the sponsor), a subsidiary of Alexion Pharmaceuticals, Inc., for the treatment of complement-related diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G). Factor D is a serine protease that catalyzes the cleavage of factor B, a rate-limiting step in the alternative pathway (AP) of complement. By inhibiting fD, ACH-0144471 potently and specifically inhibits AP activity.

Because C3G is a disease of AP hyperactivity, ACH-0144471 represents an ideal therapeutic approach to C3G, as it has the potential to reverse the underlying pathophysiology of the disease. Other renal diseases, such as primary immunoglobulin-associated membranoproliferative glomerulonephritis (MPGN), in which complement also likely plays a key role, may also be attractive as future therapeutic targets.

This protocol is a randomized, placebo-controlled, double-blinded study in which participants with C3G will receive ACH-0144471 or placebo for approximately 6 months, followed by an open-label extension of an additional 6 months and up to an additional 21 months long-term follow-up. In preceding studies, it has been demonstrated that ACH-0144471 inhibits AP activity. This study will assess whether inhibition of AP activity by ACH-0144471 results in improvements in the clinical manifestations of C3G. Doses for this study were selected based on available data from the completed and ongoing studies in healthy volunteers, and from paroxysmal nocturnal hemoglobinuria (PNH) participants and C3G patients treated in other clinical studies.

### 1.1. Previous Experience with ACH-0144471

A detailed description of the chemistry, pharmacology, efficacy, and safety of ACH-0144471 is provided in the Investigator’s Brochure [1].

### 1.2. Background

#### 1.2.1. Complement Factor D

Factor D is one of nine serine proteases in the complement system. It is a highly specific enzyme with only one known substrate, fB. Of all the complement proteins, it has the lowest abundance in serum with a concentration of approximately 2 µg/mL and is the rate-limiting step of AP activation [2, 3]. It is a low molecular weight protein (24 kDa) that is primarily produced by adipocytes, but can also be produced and secreted by monocytes/macrophages and astrocytes in humans [2, 3]. Due to its small size, it is freely filtered at the glomerulus, and then taken up by the proximal tubule cell where it is catabolized with an estimated fractional catabolic rate of 60% per hour. It is this rapid catabolism that is responsible for maintaining low circulating fD levels. As a result, renal dysfunction is associated with elevated fD levels, which may lead to increased alternative pathway activity and inflammation [4, 5]. The biochemical, physiological, and functional features of fD make it an attractive target for pharmacological inhibition as this may prove useful in the treatment of a wide spectrum of complement-mediated diseases, including C3G.

### 1.2.2. C3 Glomerulopathy

C3 glomerulopathy (C3G) is an ultra-rare disease with an incidence rate of approximately 2 per million people worldwide [6, 7]. It is widely accepted that C3G is attributable to excessive alternative pathway (AP) activity [8]. Although the disease is typically diagnosed during early adulthood in a majority of patients, the manifestations of glomerular C3 deposition can be detected in childhood and thus, it may be clinically meaningful to treat patients as young as 12 years of age [7, 9, 10]. The clinical course of C3G is characterized by variable amounts of proteinuria, hematuria, hypertension, and decreased renal function, with approximately 30% to 50% of patients reaching end-stage renal disease (ESRD) within 10 years of diagnosis [7, 11, 12, 13]. The diagnosis is based on predominant deposition of C3 in the glomerulus on renal biopsy along with clinical evidence of AP hyperactivity. C3G can be further subdivided into two separate entities, dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), based on electron microscopic features of the renal pathology [8]. Although the two disorders have similar clinical features, DDD tends to present earlier in life than C3GN. However, both diseases can present in either childhood or adulthood [13].

Unfortunately, no specific therapy has proven effective for the treatment of C3G. Care is therefore largely non-specific and supportive. Given the lack of available therapeutic options, immunosuppressive and plasma infusion/exchange therapy are often attempted, as a subset of patients may benefit [13, 14]. Treatment is otherwise focused on management of hypertension, proteinuria and the manifestations of chronic kidney disease.

The overall prognosis of C3G is poor, with approximately 30% to 50% of patients progressing to ESRD within 10 years of diagnosis. Dialysis and renal transplantation are options available for patients who reach ESRD; however, disease recurrence is frequent after transplantation, occurring in more than 50% of patients. Only about 50% of patients have a functioning graft 5 years after transplantation, which is significantly lower than renal graft survival in other settings [13, 14, 15].

Studies in animal models have indicated that the pathophysiology of C3G strongly relates to an excessive AP activity at the level of the C3 convertase. Specifically, mouse factor H-deficient animals have evidence of uncontrolled alternative pathway activation, with low plasma levels of intact C3, high levels of C3 breakdown product and renal pathology consistent with C3G; yet, in mice deficient in both factor H (fH) and fD (knock-out mice), serum C3 levels were similar to wild-type and dense deposits were not present in the kidneys [16, 17]. These studies confirmed that removal of fD prevented the renal pathogenesis of C3G in the factor H-deficient mice.

Given that the pathophysiology of C3G derives from excessive C3 activation through the AP, treatment of the disease with an AP complement inhibitor is logical. Eculizumab, the only commercially available complement inhibitor, has been tested in patients with C3G, even though its mechanism of action (targeting the terminal complement pathway) would not be expected to affect C3 activation. Based on the published results of an open-label trial in 20 patients, the general consensus is that only a subset of patients appears to benefit from eculizumab therapy; however, identification of these patients prior to treatment remains a challenge [8, 13, 14, 18]. It has been suggested that response to eculizumab may be more likely in those patients with elevated soluble C5b-9 levels, indicative of excessive terminal pathway activity, although this hypothesis remains to be established [18].

A fD inhibitor like ACH-0144471, which inhibits directly at the level of the AP C3 convertase formation, provides a more targeted rationale for efficacy than existing complement inhibitors that target the terminal complement pathway. This hypothesis is supported by animal data in which the renal disease observed with factor H deficiency, which is similar to human C3G, was completely prevented in the setting of simultaneous fD or fB deficiency [16, 17]. In contrast C5 deficiency only ameliorated, but did not prevent, renal disease. Furthermore, C6 deficiency had no effect on the renal disease in fH deficient mice. Taken together, the data from the C5 and C6 deficient mice provide evidence that the membrane attack complex itself plays little role in renal pathogenesis of C3G in the setting of fH deficiency, but that C5a production may be a factor contributing to disease [13, 19].

## **2. STUDY OBJECTIVES**

### **2.1. Primary Objective**

The primary objective of this study is to evaluate the efficacy, relative to placebo, of 6 months of oral treatment with ACH-0144471 in participants with C3G.

Evaluation of efficacy will be based on improvement in histologic scoring and proteinuria relative to baseline.

### **2.2. Secondary Objectives**

The secondary objectives of this study are:

- To evaluate the clinical effect relative to placebo, of 6 months of oral ACH-0144471 in participants with C3G based on improvement in slope of estimated glomerular filtration rate (eGFR) relative to baseline over time
- To evaluate the clinical effect, relative to placebo, of 6 months of oral ACH-0144471 in participants with C3G based on improvement in estimated glomerular filtration rate (eGFR) relative to baseline over time
- Where available, evaluate the change in measured (m) GFR relative to baseline at end of 6 months study drug treatment.
- To evaluate the safety and tolerability of 6 months of oral treatment with ACH-0144471 in participants with C3G by assessing serious adverse events (SAEs).

### **2.3. Exploratory Objectives**

#### **Complement Biomarkers**

- To evaluate the change in Complement proteins C3, Bb and Ba (split products) relative to baseline and compare these changes as they relate to clinical outcomes described in primary and secondary objectives.
- To evaluate the PK measures as they relate to complement biomarkers and alternative pathway inhibition assays (AP Weislab and AP Hemolysis)
- To evaluate the effect of -4471 therapy on complement biomarkers compared with placebo at 6 months relative to baseline

#### **2.3.1. Quality of Life Objectives**

The quality of life (QoL) objectives of the study are:

- To evaluate kidney disease and health-related quality of life instruments in participants with C3G, over the course of ACH-0144471/placebo treatment

### 3. INVESTIGATIONAL PLAN

#### 3.1. Overall Study Design and Plan

This is a randomized, placebo-controlled, double-blinded study with 6 months of dosing, followed by a 6-month open-label extended treatment period and up to an additional 21-month long-term follow-up. The study will include approximately 20 participants with C3 glomerulopathy. Participants enrolled to the protocol will be randomized 1:1 to ACH-0144471 or placebo, stratified by the disease diagnosis (DDD or C3GN) and renal function at study entry (eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup> or  $< 60$  mL/min/1.73 m<sup>2</sup>).

Participants must have a biopsy-confirmed diagnosis of C3G (C3GN or DDD, the 2 types of C3G). The initial diagnosis should have been made at least 3 months prior to dosing, unless otherwise approved by the sponsor. Participants must also have significant proteinuria (defined as  $\geq 500$  mg/day of protein in a 24-hour urine) that is attributable to C3G in the opinion of the principal investigator (PI).

For all participants, eligibility will be confirmed based on the results from the screening eligibility assessments. Once eligibility is confirmed, arrangements can be made for the “baseline” renal biopsy and/or vaccinations. The initial screening visit should occur no more than 75 days before the first dose date.

All participants should be vaccinated against *Haemophilus influenzae* (*H. influenzae*), *Streptococcus pneumoniae* (*S. pneumoniae*), and *Neisseria meningitidis* (*N. meningitidis*) to minimize the risk of serious infection with an encapsulated organism. Vaccinations should be administered at least 2 weeks before the start of dosing with ACH-0144471 according to Advisory Committee on Immunization Practices (ACIP) guidelines, as described in Section 6.3, unless otherwise recommended by national and/or local vaccination guidelines or precluded by licenses or availability. The PI may institute additional prophylactic measures, including the use of prophylactic antibiotics if deemed appropriate by local clinical practice and/or guidelines for treatment with a complement inhibitor.

The starting dosage of ACH-0144471 will be 100 mg TID, a total daily dose of 300 mg. After 2 weeks of treatment, dosing will be escalated to 200 mg TID. Additional dosage regimens may be investigated if supported by emerging data from this and other clinical studies, as described in Section 5.3.3. If treatment is discontinued, regardless of the timing or reasons for discontinuation, a 6-day taper period of the study medication is required unless the PI determines this taper period poses a risk to the participant. The taper period is in place to prevent the theoretical risk of marked increase or rebound in complement activity, as described in Section 5.2.1.


Because C3G is a serious and chronic disease, this study includes an extended treatment period which will allow participants to continue dosing for an additional 6 months or, for participants randomized to placebo for the Blinded Treatment Period, will provide the opportunity to receive ACH-0144471. All participants entering the Extended Treatment Period will receive ACH-0144471; those on active treatment will continue to receive daily treatment with ACH-0144471 and safety and efficacy monitoring, while those on placebo treatment will transition to active treatment with appropriate safety and efficacy monitoring.



This is a placebo-controlled and blinded study to the patient and site. The Sponsor and Safety team is unblinded therefore a data safety monitoring board (DSMB) is not necessary.

Patient-reported outcome (PRO) questionnaires will be administered to participants at various time points as specified in the Schedule of Assessments ([Appendix 1](#)), to assess their health-related quality of life (HRQOL), fatigue, and kidney-related fears and worries (e.g., kidney failure, dialysis, kidney transplant), and to determine health states value, over the course of treatment with ACH-0144471 or placebo. Figure 1 provides the study schematic.

**Figure 1. Study Schematic**



## 3.2. Rationale for Study Design

### 3.2.1. Justification of Design

This therapeutic trial for ACH-0144471 in C3G aims to demonstrate that factor D inhibition can reduce AP hyperactivity, and thereby halt, and possibly even reverse, progression of C3G disease. Disease progression and activity will be assessed using evaluation of clinical manifestations of the disease, namely proteinuria and abnormal eGFR and the sponsor will attempt to correlate any such improvements in clinical manifestations with changes in histopathology, to the extent biopsy data is available. A placebo-controlled, randomized, double-blinded trial was selected as a rigorous study design that minimizes the introduction of bias and misinterpretation of randomly occurring events. Further rationale is provided below for the participant population selected, the endpoints to be evaluated, the duration of treatment, and the safety monitoring plan. Rationale for dose selection and dose adjustment parameters are detailed in Section [3.2.2](#).

### 3.2.1.1. Participant Population

The participant population enrolled in this study will be patients with biopsy-confirmed C3G.

Achillion hypothesizes that a fD inhibitor will reduce AP hyperactivity, halting deposition of complement by-products in the kidney. These complement by-products induce an inflammatory response that affects glomerular function, and over time this chronic inflammation can lead to irreversible scarring of the renal parenchyma. As discussed in Section 3.2.1.2.1, the primary clinical manifestations of these processes are proteinuria and/or abnormal eGFR, and intervention during the period of active inflammation is expected to reverse damage and yield improvements in the clinical manifestations of the disease. In contrast, intervention once the kidney is irreversibly damaged may only provide minimal benefit, and even in non-ESRD participants, there is likely to be some component of irreversible renal damage that could limit the maximal response to a fD inhibitor. Therefore, we aim to enrich the population for those participants with the greatest likelihood for significant improvements by targeting participants with enough reversible renal disease to enable a detectable response to a fD inhibitor (proteinuria of at least 500 mg/day) but who do not have ESRD.

With the above in mind, we are excluding participants with an estimated GFR  $\leq 30$  mL/min/1.73 m<sup>2</sup>, and participants with more than 50% global fibrosis or more than 50% of glomeruli with cellular crescents on renal biopsy. Furthermore, to avoid inadvertent inclusion of participants with renal disease secondary to another underlying condition, or with post-infectious glomerulonephritis or another self-resolving condition that could confound interpretation of study results, participants must not have another condition to which their C3G disease is likely to be secondary.

Taken together, these criteria ensure that the appropriate population is enrolled based on the available supporting data from the clinical and nonclinical programs for ACH-0144471 at the time of study conduct.

### 3.2.1.2. Endpoints

Demonstrating definitive efficacy with well-established endpoints for renal diseases, such as time to end-stage renal disease or doubling of serum creatinine, is impractical in clinical trials for an ultra-rare disease such as C3G where these endpoints typically occur over many years, and unfortunately, there are no existing validated surrogate endpoints for progression of C3G. Achillion is therefore working with health authorities, including the FDA, to identify surrogate endpoints that are likely to predict improvement in relevant long-term outcomes. In the absence of validated surrogate endpoints, proteinuria and reduced eGFR are mechanistically important markers for glomerular loss and inflammation, as discussed in Section 3.2.1.2.1, and as such will be endpoints measured in this study.

In patients with reversible renal disease due to C3G, successful treatment should be marked by improvement in the clinical, pathologic, and laboratory evidence of the disease, namely improvements in proteinuria and/or eGFR (clinical), improvements in complement deposits and glomerular inflammation (pathologic), and correction of AP hyperactivity reflected by improvements in systemic C3 levels, as well as changes in factor B breakdown products (Bb and Ba), and other complement components (laboratory). Histology will be examined for effect of drug and changes in context of clinical improvements or stabilization of renal disease, in general

and will be correlated to signs of clinical improvement. As no other precedent exists for surrogate endpoints that reasonably predicts outcome, a co-primary endpoint of change in histology and proteinuria relative to baseline was chosen.

### 3.2.1.2.1. Clinically-Based Endpoints

Achillion has considered meaningful clinical endpoints that would be indicative of improvements in disease, based on currently available information for C3G and other primary glomerular diseases. Based on two large case series, clinical features of C3G at the time of biopsy diagnosis included proteinuria >3.5 g/day and/or nephrotic syndrome in 26.8% to 44.0%, microscopic hematuria in 64.3% to 76%, and high blood pressure in 20.7% to 44% of patients. It should be noted that at the time of diagnosis, many patients were on steroids and/or other immunosuppressive agents as well as treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which confounds interpretation of the frequency and extent of both proteinuria and high blood pressure. Regarding blood pressure, there is little additional data in the literature on the extent of high blood pressure, or its responsiveness to anti-hypertensive therapy and management, either at presentation or during the disease course. Up to 50% of patients may also have an abnormal creatinine/eGFR at time of the biopsy diagnosis. Of note, the disease can present with acute kidney injury and/or as a rapidly progressive glomerulonephritis, although these represent a minority of cases [6, 9, 20, 21, 22, 23, 24].

Considering that the primary clinical manifestations of C3G are proteinuria and/or abnormal eGFR, and that current treatment strategies heavily focus on management of these clinical features, Achillion has focused its attention on these two parameters. It is well-accepted within the nephrology community that for glomerular diseases, especially glomerulonephritis, the following earlier changes will translate to long-term clinical benefit, including renal survival: conversion of nephrotic to non-nephrotic proteinuria, decreasing proteinuria (assuming baseline proteinuria is significant [ $\geq 500$  mg/day]), eliminating proteinuria or reducing it to less than 300 mg/day, normalizing serum creatinine if abnormal at baseline, and/or improving or stabilizing eGFR relative to baseline if abnormal at baseline [25, 26, 27, 28]. Further data in the literature supports a relationship between reduction in proteinuria and improved renal survival across chronic kidney disease (CKD), and especially across multiple different primary glomerular diseases with multiple different types of interventions [29, 30, 31, 32]. Therefore, it is reasonable to expect that improvement in these clinical markers of C3G (proteinuria and/or eGFR) would be indicative of reduced glomerular injury and inflammation and would translate to improved renal survival.

As the clinical presentation and course of C3G is quite heterogeneous, patients with C3G are likely to have only a subset of the possible clinical manifestations. Given the small number of participants, it is not practical to create multiple stratified response criteria (e.g., as often done in trials for SLE nephritis) [27, 28]. Instead, the study will focus on decreasing proteinuria relative to baseline, which is expected to translate to clinical benefit. As such, the inclusion criteria require that a participant have proteinuria attributable to C3G. The study will also evaluate changes in GFR, both estimated and, where available, measured relative to baseline as a secondary endpoint.

### 3.2.1.2.2. Pathology-Based Endpoints

Renal biopsy scoring is a proximal and direct measure of renal disease. An improvement in disease activity scoring by renal histopathology is expected to translate into observed improvements in clinical manifestations, and hopefully into improvements in long-term renal outcomes. There has been no formal assessment correlating histologic features and outcomes in C3G, however, there are some data showing that the presence of crescents and more tubular atrophy in the initial biopsy are associated with worse outcomes [10, 33, 34]. In addition, the extent of C3c staining will be a key feature for biopsy analysis for this disease and considering the mechanism of action for ACH-0144471. Achillion is therefore asking for pre- and post-treatment biopsies to evaluate the effects of ACH-0144471 on renal pathology, as described in Section 6.3.1.

The pathology assessments will be described in more detail in a Pathology Manual, and the specific analysis of pathology endpoints for this study will be described in the Statistical Analysis Plan.

### 3.2.1.2.3. PRO-Based endpoints

Findings from the analysis of qualitative interviews conducted with C3G patients (n = 10) and with key opinion leaders (n = 7; clinicians and patient advocacy group leaders) have shown that C3G has a detrimental impact on patients' everyday lives. The C3G population appeared highly heterogeneous in terms of disease symptomatology, occurrence and evolution of symptoms, and level of impact on patients' lives. However, fatigue and lack of energy are the symptoms most frequently reported. In addition, patients expressed their fear and worries, mainly due to the likelihood of kidney failure, dialysis and/or transplant. In turn, this significantly affects their everyday lives and quality of life. These symptoms and impacts were salient in C3G patient testimonials during the 04 August 2017 FDA Patient-Focused Drug Development Meeting that was organized by the National Kidney Foundation. Therefore, the PRO strategy for this study will include questionnaires selected to focus on these facets of patients' lives. In particular, participants will complete PRO questionnaires (participants will complete the KDQOL-SF v1.3; FACIT-Fatigue and EQ-5D-3L questionnaires) at various time points as specified in Appendix 1, to assess their HRQOL, fatigue, and kidney-related fears and worries (e.g., kidney failure, dialysis, kidney transplant), and to determine health states value, over the course of treatment with ACH-0144471.

### 3.2.1.3. Duration of Treatment

Unfortunately, there is no precedent available for this disease to guide our decision about the length of therapy required to see improvements in clinical manifestations of renal disease (e.g., proteinuria and/or eGFR). A 6-month Blinded Treatment Period was selected following consultation with multiple C3G experts as a feasible timeframe for changes in proteinuria, eGFR and/or histopathology. Achillion is evaluating the time course of response in this investigational population, and longer dosing may be necessary; the Extended Treatment Period will therefore allow participants to continue dosing for an additional 6 months or, for participants randomized to placebo for the Blinded Treatment Period, will provide the opportunity to receive ACH-0144471 after 28 weeks. Patients may be treated for up to an additional 21 months in the long-term open-label extension.

### 3.2.1.4. Safety Monitoring Plan

The primary focus of the safety monitoring plan will be to regularly monitor safety including any adverse events, safety laboratory measurements including liver function test and serum creatinine, and the urine albumin creatinine ratio. In addition, there are specific safety monitoring plans for the potential risk of infection ([Appendix 2](#)) and elevation in liver function tests (Section [3.2.3.2](#)).

#### 3.2.1.4.1. Infection

Since one of the primary functions of the complement system is to fight infections, pharmacologic inhibition of the complement system could theoretically result in an increased rate or severity of infections. However, high doses of C1 esterase inhibitor in transplant patients with rejection did not show a signal for infection [[35](#)]. Thus, it remains unclear as to whether fD inhibition would increase risk for infection.

In vitro work was done to understand potential infection risk, especially meningococcal infection risk that is associated with AP inhibition. As summarized in Sections 4.1.2 and 6.5.1 of the Investigator's Brochure [[1](#)], ACH-0144471 showed minimal inhibition of protective bactericidal and opsonophagocytic activities in studies that included several strains of the clinically important pathogen *N. meningitidis* and blood samples from immunized individuals, suggesting that vaccination should provide protection from meningococcal infections in participants receiving ACH-0144471.

Nonetheless, this study takes steps to minimize the risk of serious infection. Participants should be vaccinated according to applicable national and/or local guidelines or local clinical practice for *N. meningitidis*, *H. influenza*, and *S. pneumonia* (see Section [6.4](#)), and antibiotic prophylaxis is permitted if deemed appropriate by local clinical practice and/or guidelines, as described in Section [6.5](#). Achillion will also create and distribute a wallet card for outpatient studies with warning signs and symptoms of serious infection, and appropriate steps of action for all participants. Finally, a fever management plan has been incorporated into the study protocol (see [Appendix 2](#)).

#### 3.2.1.4.2. Hepatic Injury

Hepatobiliary cholestasis has been observed in dog toxicology studies at exposures higher than those intended for clinical use, and higher than those planned for this study. Based on clinical observations, the cholestasis is reversible and can be monitored with hepatic safety biomarkers.

Elevations of transaminases have occurred clinically with ACH-0144471. Grade 3 or Grade 4 liver enzyme elevations occurred in 2 active phase 1 study participants receiving higher doses of ACH-0144471 (500 and 800 mg twice daily [BID]), although these elevations occurred after dosing was completed (3 days and 7 days after last dose). Elevated transaminases associated with breakthrough hemolysis have been reported in PNH studies. All abnormal transaminase findings were transient, were not associated with evidence of hepatic decompensation, and resolved within a short time period. Transaminases will be monitored in this study.

Stopping criteria have been included ensuring prompt discontinuation of any participant with evidence of unexplained liver injury. Finally, participants with evidence of active hepatic or hepatobiliary disease will be excluded.

### **3.2.2. Justification of Dose**

The starting dosage will be 100 mg TID for all participants. This dose has been demonstrated to inhibit the alternative pathway in PNH patients and in C3G patients, and dosing regimens with similar exposures (e.g., 200 mg BID) have demonstrated AP inhibition in healthy volunteers. Early data shows some clinically relevant reduction in proteinuria associated with AP inhibition, and ACH-0144471 has been well tolerated in participants with C3G. In order to maximize inhibition of the AP, the dosage will be escalated after 2 weeks, unless the participant has not tolerated treatment, or the investigator feels escalation would not be in the participant's interest. Further, because renal impairment increases factor D levels, participants with impaired renal function may require higher levels of ACH-0144471 in order to inhibit AP activity. If appropriate, additional dosage regimens may be investigated, as described in Section 5.3.3.

All parties except the sponsor will remain blinded as to whether the participant is receiving ACH-0144471 or placebo in the Blinded Treatment Period.

Based on adult pharmacokinetic data, a PBPK (physiologically based pharmacokinetics) model was developed and validated to determine a dose of ACH-0144471 in adolescents equivalent to the starting dose of 100 mg TID in adults.

### **3.2.3. Stopping Criteria and End-of-Study Definition**

The Sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the Sponsor.

A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Assessments.

#### **3.2.3.1. Study Stopping Rules**

If dosing is terminated in the study, all participants will be expected to complete the early termination activities described in Section 7.7, and comply with the schedule for the Taper Period (if relevant) and Follow-Up Period as described in Appendix 1. Of note, additional visits beyond those specified in the protocol may be required if needed to ensure adequate safety monitoring.

#### **3.2.3.2. Stopping Rules for Individual Participants**

Any individual participant who meets any of the following criteria may be discontinued from further dosing:

- The participant experiences a SUSAR
- The PI believes that participant continuation in the study is not advisable, or the participant withdraws from the study or meets one of the conditions described in Section 6.21, including, but not limited to:



- The participant becomes pregnant
- Intercurrent illness that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree
- Participant requests to discontinue for any reason

Discontinuation of treatment should also be considered for:

- ALT or AST  $>8 \times$  ULN
- ALT or AST  $>5 \times$  ULN for more than 2 weeks
- ALT or AST  $>3 \times$  ULN and concomitant total bilirubin  $>2 \times$  ULN and/or International Normalized Ratio [INR]\*  $>1.5$
- ALT or AST  $>3 \times$  ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia ( $>5\%$ )
- If there is a marked prolongation of the QT/QTc interval during treatment with the study drug, especially if the measurement is obtained from more than one ECG

\* Participants, particularly those with nephrotic syndrome, may be receiving ongoing warfarin, resulting in increased INR values. The PI should evaluate INR in the context of any concomitant medications to determine if any observed increases are due to an effect on liver function or are secondary to anticoagulation.

The PI may stop dosing or reduce dosing in any participant who meets an Individual Stopping Rule; however, the Achillion Medical Monitor (MM) should be notified immediately, and if possible, before dosing is reduced or terminated. When dosing is stopped in an individual participant, the PI should consider whether it is in the best interest of the participant to discontinue dosing immediately or to taper (as described in Section 5.2). Whenever possible, the taper decision should also be discussed with the Achillion MM prior to dosing termination. Further continuation in the study should be discussed with the Achillion MM.

Upon dosing termination and study discontinuation, a participant will be expected to complete the early termination activities described in Section 7.7, and comply with the schedule for the Taper Period (if relevant) and Follow-Up Period as described in Appendix 1. Of note, additional visits beyond those specified in the protocol may be required if needed to ensure adequate safety monitoring.

## 4. STUDY POPULATION SELECTION

### 4.1. Study Population

This study will be conducted in approximately 20 participants, with biopsy-confirmed DDD or C3GN who have not undergone renal transplant, and who have significant proteinuria (defined as  $\geq 500$  mg/day of protein in a 24-hour urine) and an eGFR  $>30$  mL/min/1.73 m<sup>2</sup>.

### 4.2. Inclusion Criteria

Each participant must meet all the following criteria to be enrolled in this study.

1. Must have biopsy-confirmed primary C3G
2. Must be 17 years of age or older and capable of swallowing tablets
3. Must have clinical evidence of ongoing disease based on significant proteinuria (defined as  $\geq 500$  mg/day of protein in a 24-hour urine or equivalent on spot urine) attributable to C3G disease in the opinion of the PI, and present prior to study entry and confirmed during Screening
4. If on corticosteroids, anti-hypertensive medications, anti-proteinuric medications (e.g., ACE inhibitors or angiotensin receptor blockers [ARBs]), or mycophenolate mofetil (MMF), must be on a stable dose for at least 2 weeks prior to screening
5. Female participants of childbearing potential must agree to use an acceptable method of contraception (as defined in Section 5.5.4) from the date of signing the informed consent to the first day of dosing (Day 1), and must agree to use a highly effective form of contraception (as defined in Section 5.5.4) from the first day of dosing to 30 days after their last dose of study drug. Female participants of childbearing potential must also have a negative serum pregnancy test during Screening and negative urine pregnancy test on Day 1. Female participants of non-childbearing potential need not employ a method of contraception
6. Non-sterile male participants must agree to use a highly effective form of contraception (as defined in Section 5.5.4) with their partner(s) of childbearing potential from the first day of dosing to 90 days after their last dose of study drug.  
  
Male participants who are surgically sterile need not employ additional contraception.  
  
Male participants must agree not to donate sperm while enrolled in this study and for 90 days after their last dose of study drug.
7. Adult participants must be capable of providing written informed consent and adolescent participants must be capable of providing written assent. All participants must be willing and able to comply with the requirements and restrictions listed in the consent form and with all procedures in the protocol, including, the visit schedule, the treatment plan, the schedule for laboratory testing, and other study procedures
8. Must be up-to-date on routine vaccinations, or willing to be brought up-to-date, based on local guidelines
9. Must have access to emergency medical care.



### 4.3. Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study.

1. Have a history or presence of any clinically relevant co-morbidities that would make the participant inappropriate for the study (for example, a comorbidity which is likely to result in deterioration of the participant's condition, affect the participant's confound the results of the study), in the opinion of the PI
2. Have ever received ACH-0144471
3. Have a pre-treatment renal biopsy, or a biopsy collected within approximately 6 months of the start of dosing and available for review, which shows more than 50% global fibrosis or more than 50% of glomeruli with cellular crescents
4. Have an estimated GFR  $<30$  mL/min/1.73 m<sup>2</sup> at the time of screening or at any time over the preceding four weeks
5. Is a renal transplant recipient or receiving renal replacement therapy
6. Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
7. Have evidence of monoclonal gammopathy of unclear significance (MGUS), infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary
8. Have other renal diseases that would interfere with interpretation of the study
9. Have been diagnosed with or show evidence of hepatobiliary cholestasis
10. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration
11. Have a history of febrile illness, a body temperature  $>38^{\circ}\text{C}$ , or other evidence of a clinically significant active infection, within 14 days prior to study drug administration
12. Have evidence of human immunodeficiency virus (HIV), hepatitis B infection, or active hepatitis C infection at Screening
13. Have a history of meningococcal infection within the prior year
14. Have a history of hypersensitivity reactions to commonly used antibacterial agents, including beta-lactams, penicillin, aminopenicillins, fluoroquinolones, cephalosporins, and carbapenems, which, in the opinion of the investigator and/or an appropriately qualified immunology or infectious disease expert, would make it difficult to properly provide either empiric antibiotic therapy or treat an active infection.
15. Have participated in a clinical study in which an investigational drug was given within 30 days, or within 5 half-lives of the investigational drug, whichever is longer, prior to the first dose of study drug
16. Have received eculizumab at any dose or interval within the past 50 days prior to the first dose of study drug
17. Have received tacrolimus or cyclosporine within 2 weeks of the first dose of study drug

18. Have any of the following laboratory abnormalities at screening:

- Alanine transaminase (ALT) > upper limit of normal (ULN)
- Aspartate aminotransferase (AST) > ULN
- Absolute neutrophil counts (ANC) <1,000/ $\mu$ L
- Total bilirubin >1.5 $\times$  ULN
- Indirect bilirubin > ULN
- Any laboratory abnormality that, in the opinion of the PI, would make the participant inappropriate for the study

19. Are unwilling or unable to comply with the study protocol for any reason

## **5. STUDY TREATMENT(S)**

### **5.1. Description of Treatment(s)**

#### **5.1.1. Study Drug**

Throughout this protocol, “study drug” should be understood to refer to the treatment being evaluated. During the Blinded Treatment Period, this may be either ACH-0144471 or placebo, but neither the participants or the investigators, will know which an individual participant is receiving. During the Extended Treatment Period, “study drug” will be ACH-0144471.

#### **5.1.2. ACH-0144471**

ACH-0144471 will be dosed orally as a tablet formulation containing the drug substance, lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulphate, magnesium stearate, colloidal silicon dioxide, and hypromellose acetate succinate. The coating components are polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, and talc. Tablets will be provided in 50, and 100-mg strengths.

#### **5.1.3. Placebo**

Matching placebo tablets will contain lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulphate, magnesium stearate, colloidal silicon dioxide, and hypromellose acetate succinate. The coating components are polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, and talc.

### **5.2. Treatment(s) Administered**

#### **5.2.1. ACH-0144471 or Placebo**

ACH-0144471 or matching placebo tablets will be administered at a starting dosage of 100 mg TID on Day 1. After 2 weeks of treatment, dosing will be escalated to 200 mg TID, as for an additional 26 weeks (Blinded Treatment Period). On completion of the Blinded Treatment Period, participants may continue in the Extended Treatment Period, and Long-Term Follow-up Period during which all participants will receive ACH-0144471 as described in Section 5.3. If there is a gap prior to starting the Extended Treatment Period, Long-Term Follow-up Period or if dosing is discontinued, the dose should be tapered over approximately 6 days to minimize the potential adverse effects of a rapid surge in complement activity following drug withdrawal.

Dosing taper regimens are described in Table 1. If a dosing regimen not specified in the Table 1 is used, then the taper regimen will be defined by the Achillion MM prior to dosing termination. In addition, the taper regimen may be adjusted if the sponsor or investigator feels it would be appropriate to do so (e.g., to allow for slower taper in a participant who is not tolerating discontinuation of drug, or for other reasons).

**Table 1. ACH-0144471 Taper Schedule**

<b>Dose at Termination</b>	<b>Taper Period 1 (Taper Days 1-3)</b>	<b>And Taper Period 2 (Taper Days 4-6)</b>
100 mg TID	100 mg BID	0 mg BID
200 mg TID	100 mg TID	100 mg BID

**5.2.2. Vaccines**

Depending on the participant's vaccination history, the vaccines described in Section 6.4 may need to be administered to participants according to ACIP guidelines, unless otherwise recommended national and/or local vaccination guidelines or precluded by licenses or availability. Because these are commercially available products, information about the specific vaccines can be found on the package inserts/product labels for those products. Full identifying information for any administered vaccines, including the brand, should be recorded in the participant's CRF.

**5.2.3. Prophylactic Antibiotics**

As described in Section 6.5, antibiotic prophylaxis is not mandated but allowed if deemed necessary by local clinical practice and/or guidelines for treatment with a complement inhibitor. Because commercially available products will be used, information about any specific antibiotics administered can be found on the package inserts/product labels for those products.

For any antibiotics given as part of this study, full identifying information, including the brand, should be recorded in the participant's CRF.

**5.3. Selection of Timing and Dose for Each Participant**

For the starting dose, participants will take one 100-mg ACH-0144471 or matching placebo tablet three times daily (TID): a dose in the morning, a second dose 8 hours later, and a third dose 8 hours after the second dose. Doses should be taken at approximately the same time each day and as close as possible to 8 hours apart. All doses should be taken approximately 15 to 30 minutes after completion of a meal. Water intake is not restricted. If a dose is missed, it should be taken within 4 hours of the originally scheduled time. After 4 hours, the missed dose should be skipped. In either case, the next dose should be taken according to the original dosing schedule.

If a dosing interval other than TID is used during the study, then interval between doses should be equally distributed over a 24-hour period, and dosing should otherwise comply with the guidelines provided for a TID interval.

All participants will receive ACH-0144471 in the Extended Treatment Period. While the blinded portion of the study is ongoing, the treatment assignment for a given participant will not be known. In order to maintain the overall blind, all participants will start the Extended Treatment Period. The timing, intervals, and makeup of the doses will follow the above instructions.

**5.3.1. Clinic Visit Dose Administration Instructions**

Participants will be instructed to fast for at least 8 hours before their clinic visit, and to drink enough water to ensure they are adequately hydrated. Participants must abstain from taking their

study medication on the mornings of their study visits so that they can be dosed in the clinic following safety and pharmacokinetic assessments. All doses should be taken approximately 15 to 30 minutes after completion of a meal. Participants will be required to bring back their study drug at each visit so that study site personnel may perform drug accountability. If morning clinic visits are not possible, participant visits may be scheduled so that safety and pharmacokinetic assessments can be made before the second daily dose. The 8-hour interval between doses should be maintained, as should the relative timing of dosing and all study-related activities.

### **5.3.2. Home Dose Administration Instructions**

Participants should be instructed to finish a meal or snack approximately 15 to 30 minutes prior to dosing. Doses should be taken at approximately the same time each day and as close as possible to 8 hours apart (or the relevant interval in the event of a non-TID schedule).

Participants should be instructed to keep their study medications at room temperature.

### **5.3.3. Dose Adjustment**

After 2 weeks of treatment, dosing will be escalated to 200 mg TID unless the participant has not tolerated treatment, as determined by the medical monitor. While the intent is to maintain a steady dose for the duration of the study, additional dose adjustments are permitted if it is felt to be in the participant's interest. Further, because renal impairment increases factor D levels, participants with impaired renal function may require higher levels of ACH-0144471 in order to inhibit AP activity. If supported by emerging data from this and other clinical studies, additional dosage regimens may be investigated. Dosing may be adjusted by the MM (or designee) in consultation with the PI within the parameters provided below.

- Dose adjustments can include changes in dose amount (e.g., change from 100 to 200 mg per dose) or in dose frequency (e.g., change from TID to BID or QID).
- While treatment is blinded, the decision to dose escalate will be made without breaking the treatment blind.
- Dose increases should be such that the new total daily dose is no more than 2× the prior total daily dose.

## **5.4. Method of Assigning Participants to Treatment Groups**

Participants enrolled will be randomized 1:1 to either active treatment (ACH-0144471) or placebo, stratified by disease diagnosis (DDD or C3GN) and renal function at study entry (eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup> or  $< 60$  mL/min/1.73 m<sup>2</sup>).

A centralized Interactive Web Response System (IWRS) will be used to generate a randomization scheme to provide treatment assignment of either ACH-0144471 or placebo to each participant in a 1:1 ratio. The randomization will be stratified by renal function at study entry and disease diagnosis as stated above. The randomization block design will be utilized within each stratum. The process of obtaining blinded treatment assignment for each participant will be documented in the laboratory manual.

If it is necessary to unblind a study participant due to an emergency requiring knowledge of the participant's treatment group for medical management, the investigator may perform the unblinding via the IWRS by entering the participant's identifiers. The PI does not need prior approval from the Sponsor in order to unblind; however, the PI should notify the medical monitor as soon as possible regarding the unblinding decision and rationale.

Although all participants will receive active drug during the open-label Extended Treatment Period, the first portion of the study will not be unblinded until all participants have completed the Blinded Treatment Period.

## **5.5. Restrictions**

### **5.5.1. Prior and Concomitant Therapy**

Participants may not have received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to the first dose of study drug, whichever is greater. Participants may not have received eculizumab within 50 days prior to the first dose of study drug. Participants may not have received tacrolimus or cyclosporine within 2 weeks prior to the first dose of study drug.

Based on in vitro data, ACH-0144471 has the potential to interact with several CYP enzymes as well as some transporters as a perpetrator but not as a victim drug. In vitro results for various CYP enzymes and transporters are described in the Investigator's Brochure [1].

A drug-drug interaction study with ACH-0144471 has been conducted to determine the potential for ACH-0144471 to affect the PK of midazolam (substrate for CYP3A), fexofenadine (substrate for P-gp), and mycophenolic acid (substrate of UGT). Preliminary results indicate that ACH-0144471 is a weak inhibitor of CYP3A, a moderate inhibitor of P-gp, and had no effect on UGT.

Use of specific concomitant medications will be considered on a case-by-case basis, with decisions made jointly between the PI and Sponsor, based on available and emerging knowledge of ACH-0144471 as well as the characteristics of the potential concomitant medication. Details of all concomitant medication use, including all medications administered for the treatment of AEs, must be recorded in the participant's case report form (CRF). The following are some general guidelines for concomitant medication use based on currently available data:

- Concomitant administration of cyclosporine and tacrolimus are not allowed and must be stopped at least two weeks prior to study drug administration.
- Concomitant administration of corticosteroids is permitted if on stable doses for at least 2 weeks prior to the first screening visit. Doses should be maintained at the same dose throughout the study, whenever possible, unless the PI deems it necessary to do otherwise.
- Concomitant administration of mycophenolate mofetil (MMF) is allowed if on stable doses for at least 2 weeks prior to the first screening visit. Doses should be maintained at the same dose throughout the study, whenever possible, and unless the PI deems it necessary to do otherwise.
- Concomitant administration of warfarin or low molecular weight heparin is permitted.

- Oral, injectable, implantable, transdermal, or intravaginal hormonal therapies are allowed for either contraception or hormonal replacement therapy.
- Concomitant administration of anti-proteinuric medications (e.g., ACE inhibitors or ARBs) or anti-hypertensive medications is permitted if on stable doses for at least 2 weeks prior to the first screening visit. Doses should be maintained at the same dose throughout the study, whenever possible, unless the PI deems it necessary to do otherwise.
- If it is necessary to treat a fever (see [Appendix 2](#)), or any minor ailment occurring while on study, ibuprofen (maximum 400 mg/day and up to 1200 mg/week) and/or acetaminophen (maximum 1000 mg/day) are permitted without prior approval.
- Antibiotic prophylaxis is allowed if deemed appropriate by local clinical practice and/or guidelines for treatment with a complement inhibitor.

No new therapy should be added during the study unless the participant's condition deteriorates to the extent that the PI deems it in the best interest of the participant to do so. In addition, doses of medications for C3G (e.g., immunosuppressive agents, ACE inhibitors, etc.), should be maintained at the same dose throughout the study, whenever possible, and unless the PI deems it necessary to do otherwise.

#### **5.5.2. Fluid and Food Intake**

Participants should be instructed to take each dose of study drug within 15 to 30 minutes of finishing a meal or snack.

Water or other non-alcoholic fluid intake is not restricted.

#### **5.5.3. Participant Activity and Other Restrictions**

Participants should refrain from heavy exercise 24 hours prior to and after having blood drawn for safety laboratory evaluations. Walking and light exercise are acceptable.

#### **5.5.4. Contraception**

##### **5.5.4.1. Contraception for Male Participants**

All non-sterile male participants must use highly effective or acceptable contraception with their partner(s) of childbearing potential from the first day of dosing (Day 1) through 90 days after their last dose of study drug.

Sterile is defined as having bilateral orchiectomy.

Highly effective contraception for males is defined as any of the following:

- Vasectomy with confirmed medical assessment of surgical success
- Condom plus use of one of the following by partner(s) of child-bearing potential:
  - Oral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation

- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
- Intrauterine device (IUD) or Intrauterine hormone-releasing system (IUS)
- Bilateral tubal occlusion (including bilateral tubal ligation)
- Sexual abstinence, defined as refraining from heterosexual intercourse during the entire period from the first day of dosing (Day 1) through 90 days after their last dose of study drug. Periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. If a participant is usually not sexually active but becomes active, they, with their partner(s), must comply with the contraceptive requirements described in this section.

Acceptable contraception for males or female partner of childbearing potential is defined as any of the following:

- Progestin-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
- Male or female condom with or without spermicide
- Cap, diaphragm, or sponge with spermicide
- Combinations of male condom with either cap, diaphragm, or sponge with spermicide (double-barrier methods)

Male participants must agree to refrain from sperm donation from the date of screening until 90 days after their last dose of study drug.

#### **5.5.4.2. Contraception for Female Participants**

Female participants of child-bearing potential and/or their male partners must use a highly effective or acceptable method of contraception from the date of signing the informed consent to the first day of dosing (Day 1), through 30 days after their last dose of study drug.

Highly effective contraception for females is defined as any of the following:

- Oral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
- Intrauterine device (IUD) or Intrauterine hormone-releasing system (IUS)
- Bilateral tubal occlusion (including bilateral tubal ligation)
- Vasectomised partner(s) with confirmed medical assessment of surgical success
- Sterile partner(s) (bi-lateral orchiectomy)



- Sexual abstinence, defined as refraining from heterosexual intercourse during the entire period from the first day of dosing (Day 1) through 30 days after their last dose of study drug. Periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. If a participant is usually not sexually active but becomes active, they, with their partner(s), must comply with the contraceptive requirements described in this section.

Acceptable contraception for females is defined as any of the following:

- Progestin-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
- Male or female condom with or without spermicide.
- Cap, diaphragm or sponge with spermicide
- Combinations of male condom with either cap, diaphragm, or sponge with spermicide (double-barrier methods)

Female participants of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline in order to enter the study, and must have urine pregnancy tests throughout the study at the intervals defined in the Schedule of Assessments ([Appendix 1](#)).

Female participants of non-childbearing potential, as defined by one of the following, need not employ a method of contraception:

- Surgical sterilization by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy
- Postmenopausal with amenorrhea for at least 1 year prior to dosing and FSH serum levels consistent with postmenopausal status

## 5.6. Treatment Compliance

Treatment compliance assessments shall be performed at each visit. Participants will be required to bring their supply of study drug to each visit so that study site personnel may perform drug accountability. Site personnel will keep a record of all drug dispensed and returned at each visit. Drug dispensing records will be updated at each visit.

Participants will be asked to record the time they take each daily dose of study drug and may receive automated reminders (e.g., via SMS text or phone call) in an effort to ensure compliance. The site will receive notification of any non-response or non-compliance to follow up and address with the participant directly.

## 5.7. Packaging and Labeling

Labels for ACH-0144471 and placebo tablets will include, at a minimum, the following information, in English:

- Clinical Study Number
- Sponsor Name and Address

- Product Name and Strength
- Dosage Form and Route of Administration
- Direction for Use
- Contents (Number of Tablets)
- Randomization Number
- Storage Instructions
- Caution statement to keep out of the reach of children
- Caution Statements such as “For Clinical Trial Use Only” or “Caution: New Drug-Limited by Federal (or United States) law to investigation use” or similar statements

### **5.8. Storage and Accountability**

At the pharmacy, the ACH-0144471 and placebo tablets must be stored as provided at controlled room temperature (20°C to 25°C), with allowed excursion of 15°C to 30°C. Participants should be instructed to keep their study medications in the original container at room temperature.

Participants will be required to bring back their study drug at each clinic visit so that study site personnel may perform drug accountability.

The PI or designee (e.g., pharmacist) is responsible for ensuring storage as per the label on the drug product at the site and adequate accountability of all used and unused study drug. This includes acknowledgment of receipt of each shipment of study drug (quantity and condition) and participant dispensing records and returned or destroyed drug. Dispensing records will document quantities received from Achillion Pharmaceuticals (or designee) and quantities dispensed to participants, including lot number, date dispensed, participant identifier number, participant initials, and the initials of the person dispensing the medication. All drug supplies and associated documentation will be periodically reviewed and verified by the Study Monitor over the course of the study.

### **5.9. Investigational Product Retention at Study Site**

At study initiation, the Study Monitor will evaluate the site’s Standard Operating Procedure for study drug disposal/destruction in order to ensure that it complies with Achillion Pharmaceuticals requirements. Drug may be returned to the Sponsor (or designee) or destroyed on an ongoing basis during the study, if appropriate, after drug accountability has been verified by the Study Monitor. At the end of the study, following final drug inventory reconciliation by the Study Monitor, the study site will dispose of and/or destroy all unused study drug supplies, including empty containers, according to these procedures. If the site cannot meet Achillion Pharmaceuticals requirements for disposal, arrangements will be made between the site and Achillion Pharmaceuticals or its representative, for destruction or return of unused study drug supplies.

## **6. STUDY PROCEDURES**

The required study procedures are detailed in this section. The timeline for these procedures may be found in [Appendix 1](#).

### **6.1. Informed Consent**

The PI or designee is responsible for administering and obtaining freely given consent, in writing, before the participant enters into the study and any study-related procedures are performed. Each adult participant will sign an Ethics Committee (EC) or Institutional Review Board (IRB)-approved written informed consent form (ICF). This may include additional consent forms for HIV testing or other procedures which may be performed prior to participants being accepted into the study.

### **6.2. Medical History**

At Screening, the PI or designee will interview each participant and obtain a complete medical and medication history to determine whether the participant meets the eligibility criteria. The history should include the specific type of C3 glomerulopathy (C3GN or DDD), date of initial C3G diagnosis, family history of renal disease, all surgeries and past medical procedures, all past significant illnesses or current chronic conditions, all medication use currently and within the past 90 days (including over the counter medications, and use of herbal and nutrient supplements), any prior use of alcohol, illicit drugs and/or controlled substances, and any other relevant information. Other relevant information should include all available GFR or eGFR values for the past year, and any extrarenal manifestations of C3G, including ophthalmic manifestations such as drusen. If any ophthalmic exams are performed (including any exams performed for reasons unrelated to the conduct of this study), then every effort will be made to include an anonymized copy of the exam results in the participants' source documents. The history should also include the results of any genetic testing related to the disease, and a full vaccination history. The medical history must be recorded in the participant's source documents and in the participant's CRF.

### **6.3. Percutaneous Renal Biopsy**

Percutaneous renal biopsies should be performed according to local practices for this procedure, including appropriate pre-biopsy evaluation, biopsy technique, choice of imaging technique (e.g., ultrasound-guided, CT-guided, or other), anesthesia, and post-biopsy care. All biopsies will be reviewed by the designated central pathology laboratory, and will be evaluated by light microscopy, electron microscopy and immunofluorescence.

Details on the processing of the biopsy sample and discussion of the final renal pathology assessment and scoring for this study will be provided in the Pathology Manual, and the method for analyzing the pathology data will be provided in the Statistical Analysis Plan. However, the approach will be like that described for lupus in that it will assess features that indicate active glomerular inflammation, and those that indicate chronic fibrotic irreversible injury. Each of these will be quantitated and may be combined into a composite scoring system. If a composite scoring system is not used, the score of each feature at baseline and post-treatment can be compared.

If, for any reason, any additional renal biopsies are performed (e.g., for a clinical indication), then every effort will be made to make these biopsy samples and results available to the central pathology laboratory for evaluation.

### 6.3.1. Renal Biopsy

Participants should have a renal biopsy before the first dose of ACH-0144471 to establish a baseline histology score. Only one biopsy will be obtained prior to dosing; if a biopsy is required to confirm the diagnosis of C3G, it will be considered the pre-treatment biopsy. If a participant has had a recent renal biopsy it may not be clinically reasonable to repeat the procedure, and in this situation, a biopsy collected within approximately 6 months of the first dose of study drug may be accepted in lieu of a biopsy during screening if it meets the requirements for analysis, and with written sponsor approval prior to study enrolment.

For all subjects, a biopsy should be obtained at the end of the Blinded Treatment Period (approximately Week 28), as defined in [Appendix 1](#), to allow evaluation of changes in renal pathology. If not contraindicated, an additional biopsy may be obtained at the end of the Extended Treatment Period.

A sub-study is being conducted to evaluate the effects of ACH-0144471 on renal pathology; participation in this sub-study is not required. A separate informed consent will be required for participation.

Participants who choose to participate in the sub-study should have a renal biopsy at Week 52 and 104 as detailed on the Schedule of Assessments.

## 6.4. Vaccination

Information regarding the risk of infection can be found in Section 6.5.1 of the Investigator's Brochure [1].

As discussed in Section 6.2, a full vaccination history will be gathered. Based on the vaccination history, the need for vaccinations against *N. meningitidis*, *S. pneumoniae*, and *H. influenzae* in this study will be evaluated. Study participants who do not have a sufficient history for some or all of these vaccines should receive vaccinations at least 2 weeks before the start of dosing with ACH-0144471 as recommended in the Advisory Committee on Immunization Practices (ACIP) guidelines, unless otherwise recommended by national and/or local guidelines or local clinical practice. If local and/or national guidelines do not exist or do not fully address vaccination against these organisms, investigators should consider consulting the ACIP guidelines (available at <https://www.cdc.gov/vaccines/acip/index.html>).

Full identifying information for any vaccines given as part of this study, including the brand, should be recorded in the participant's CRF.

## 6.5. Prophylactic Antibiotics

As described in Section 6.4, Achillion expects that participants will be vaccinated according to ACIP guidelines at least 2 weeks prior to dosing with ACH-0144471 and believes that this will provide sufficient protection against these organisms. However, this is a global study and Achillion recognizes that some vaccines may not be available in all countries, and that guidelines

and clinical practices differ by region and may include the use of prophylactic antibiotics in some instances. Antibiotic prophylaxis is therefore allowed if deemed appropriate by the PI or local clinical practice and/or guidelines for treatment with a complement inhibitor.

Full identifying information for any antibiotics given as part of this study, including the brand, dosage, and times of administration should be recorded in the participant's CRF.

## **6.6. Urine Collection**

### **6.6.1. 24-Hour Urine Collection**

Collection of urine over 24 hours will occur according to the Schedule of Assessments ([Appendix 1](#)). Urine collected will be assayed as described in [Table 2](#) for total protein concentration, albumin and creatinine concentrations, albumin:creatinine ratio, total protein:creatinine ratio, and total volume. Complement components may also be assessed using urine, as described in [Section 6.13.1](#).

The 24-hour urine collection period may be at any time during screening, but if it is to occur after a renal biopsy, it must be at least 7 days after the biopsy procedure. If clinic visits are not possible during the COVID-19 global pandemic, urine samples may be collected during home healthcare visits or delivered to a local laboratory.

Specific instructions for urine collection, processing, and shipping will be provided in the laboratory manual.

### **6.6.2. First Morning Urine Collection**

Collection of urine will occur according to the Schedule of Assessments ([Appendix 1](#)). Urine collected will be assayed as described in [Table 2](#); in addition to standard urinalysis, urine collected will be assayed for total protein concentration, albumin and creatinine concentrations, and the protein:creatinine and albumin:creatinine ratios. Complement components may also be assessed, as described in [Section 6.13.1](#).

Participants will be given a collection container to collect their first morning void. Specific instructions for urine collection, processing, and shipping will be provided in a separate laboratory manual. If the first morning urine collection coincides with a renal biopsy, collection must be completed before or at least 7 days after the biopsy procedure. If clinic visits are not possible during the COVID-19 global pandemic, urine samples may be collected during home healthcare visits or delivered to a local laboratory.

## **6.7. Physical Examination**

A complete physical examination will be conducted by the PI (or designee) at the times specified in the Schedule of Assessments ([Appendix 1](#)). This will include an examination of all major body/organ systems (including skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, heart, abdomen, lymph nodes, and extremities), height, weight and calculation for BMI. Measurements of height and weight should be taken with the participants in light clothing or underwear and without shoes. Assessment of edema is part of the complete physical exam. If edema is present,

then assessment of edema should be performed at each subsequent visit, even when a physical exam is not required.

Brief physical examinations, to include general appearance and examination of cardiovascular and respiratory systems, abdomen, extremities, and skin will be performed by the PI (or designee) at the times specified in the Schedule of Assessments ([Appendix 1](#)). Assessment of edema is part of the brief physical exam. If edema is present, then assessment of edema should be performed at each subsequent visit, even when a physical exam is not required. Additional complete, brief or targeted physical exams (e.g., targeted to any new signs or symptoms) may be performed at any time at the discretion of the Investigator or designee, for example to evaluate an AE. All clinically significant physical examination findings that are new or worsened since the last physical examination must be recorded in the participant's source documents and in the participant's CRF as an adverse event.

## **6.8. Vital Signs**

The PI or designee will obtain blood pressure (BP), heart rate (HR), and respiration rate (RR) at the visits indicated in the Schedule of Assessments ([Appendix 1](#)). Vital signs will be measured in the supine position following a 5-minute rest. All blood pressure measurements should be taken on the same arm throughout the study. Vital signs may be measured using an automated vital sign monitor, although manual measurements of blood pressure are preferred. All vital sign measurements must be done using a calibrated instrument. For each participant, the same method of measurement should be used at all visits. All vital sign values, including whether measured manually or via an automated monitor, will be recorded in the participant's source documents and in the participant's CRF.

## **6.9. Body Temperature**

The PI or designee will obtain body temperature using an oral thermometer at the visits indicated in the Schedule of Assessments ([Appendix 1](#)). Prior to discharge from the clinic on Day 1, the participant will:

1. Be educated and counseled by site staff regarding the potential for serious, rapidly progressive bacterial infections which may be life threatening and therefore understand the need to identify fever rapidly and seek emergency medical evaluation without delay
2. Be educated and counseled by site staff regarding high risk behaviors, which include drinking from the same beverage containers, sharing eating utensils with others, avoiding large crowds, and smoking (including second-hand exposure)
3. Be provided a thermometer and taught how to use it. All participants need to take these thermometers with them at all times. They need to be able to take their temperature if feeling warm or unwell
4. Be instructed to contact the investigator immediately and/or seek emergency medical attention for any temperature  $>38.0^{\circ}\text{C}$  /  $100.4^{\circ}\text{F}$
5. Be advised not to wait for site staff to return their phone call before seeking emergency medical attention but should go to the nearest emergency or urgent care medical facility for evaluation.

6. Be taught to be alert to the signs of possible serious infections, which are often flu-like symptoms
7. At all times, have immediate access to transportation and telephone, and be within reasonable proximity to emergency medical care
8. Be provided with a study contact card and instructed to carry this with them at all times. The study contact card should be provided to the emergency medical personnel who should be asked to contact the study site

All abnormal body temperature measurements must be recorded or stored in the participant's source documents and CRF. Any clinically significant finding must be reported as an adverse event. Any temperature measurement  $\geq 38.0^{\circ}\text{C}$ , measured either at the clinic or by the participant outside the clinic, requires action as outlined in the Fever Management Plan ([Appendix 2](#)).

## 6.10. Electrocardiography

The PI or designee will obtain a screening ECG measurement, as indicated in [Appendix 1](#). All ECG recordings should be 12-lead, and should be performed after the participant has rested quietly for at least 5 minutes in a supine position prior to dosing and before blood is drawn (whenever possible). The following parameters and intervals will be assessed: HR, RR, PR, QRS, QT, and QTcF. The occurrence of depolarization or repolarization disorders, arrhythmic disorders or other abnormalities will be noted. A designation of clinical significance shall also be noted.

In some cases, it may be appropriate to repeat an abnormal ECG to rule out improper lead placement as contributing to the ECG abnormality. It is important that the leads are placed in approximately the same positions each time in order to achieve precise ECG recordings.

All ECGs must be read by the PI or designee. The PI/designee needs to evaluate the finding of ECG abnormalities promptly (refer to Section [6.18.1](#) for a discussion of the circumstances under which ECG findings are to be reported as AEs).

All ECG parameters and assessments must be recorded or stored in the participant's source documents and in the participant's CRF. Any clinically significant finding must be reported as an adverse event.

## 6.11. Clinical Laboratory Tests

Blood and urine samples will be collected for safety and PD laboratory evaluation as listed in [Table 2](#), at the times in [Appendix 1](#). Participants will be in a seated or supine position during the blood collection. Specific instructions for sample collection, processing, and shipping will be provided in a separate laboratory manual.

In addition to the calculation of eGFR, some investigators may choose to measure GFR based on iothexol clearance. Measurement of GFR is at the discretion of the investigator, but if performed, these measurements should be taken, at a minimum, in accordance with the Schedule of Assessments. Additional measurements may also be done at the discretion of the investigator.



**Table 2. Clinical Laboratory Tests**

Hematology	Chemistry	Urinalysis	Additional Tests at Screening Only	Other Assessments
Complete blood count (CBC), including: - Red blood cell (RBC) count - White blood cell (WBC) count - WBC differential (absolute and percent): - neutrophils - lymphocytes - monocytes - eosinophils - basophils - Hematocrit (Hct) - Hemoglobin (Hgb) - Mean corpuscular volume (MCV) - Mean corpuscular hemoglobin (MCH) - Mean corpuscular hemoglobin concentration (MCHC) - Mean platelet volume (MPV) - Platelet count - Red cell distribution width (RDW) - Reticulocyte count	Alanine aminotransferase (ALT) Albumin Alkaline phosphatase Aspartate aminotransferase (AST) Bicarbonate (HCO <sub>3</sub> ) Bilirubin (fractionated) <sup>1</sup> Blood urea nitrogen (BUN) Calcium Calculated eGFR <sup>2</sup> Chloride Creatinine Cystatin C Gamma-glutamyl transferase (GGT) Glucose <sup>3</sup> GFR (iohexol clearance) <sup>4</sup> Lipid Profile including: - Cholesterol/HDL ratio - High-density lipoprotein cholesterol (HDL-C) - Low-density lipoprotein cholesterol (LDL-C) - Non-HDL-C - Total cholesterol - Triglycerides - Very low-density lipoprotein cholesterol (VLDL-C) Phosphate Potassium Sodium Total protein Uric acid	Dipstick Analysis including: - Bilirubin - Color - Glucose - Ketones - Leukocytes - Nitrite - Occult blood - pH - Protein - Specific gravity - Urobilinogen  Microscopic examination of sediment <sup>5</sup>  Spot Urine and 24-Hour Urine samples <sup>6</sup> : - Total protein - Albumin - Creatinine - Albumin: creatinine ratio - Total protein: creatinine ratio - Complement components	HCV Ab <sup>7</sup> HbsAg HIV Ab FSH <sup>8</sup> Serum Pregnancy test <sup>9</sup> Urine drug screen <sup>10</sup> Sample for potential genetic biomarker testing (white blood cells)	Serum/Plasma Complement Biomarkers: - C3 Convertase - AP Hemolysis - AP Wieslab - Ba - Bb - C3 - C4 - CP activity - fD - sC5b-9 - C3a - C5 - Multiplex assay (fB, fH, properdin) - Auto-antibodies to fH - C3 nephritic factor PT/PTT/INR Urine pregnancy test <sup>9</sup>

Check the Schedule of Assessments ([Appendix 1](#)) for specific times when these tests should be done.

1 Fractionate and obtain measurements of direct and indirect bilirubin for all participants.



- 2 Provide eGFR based on CKD-EPI creatinine equation (2009) for participants  $\geq 19$  years of age, and based on the “Bedside Schwartz” equation (2009) for participants  $< 19$  years of age.
- 3 If glucose is  $> \text{ULN}$ , reflexively test HbA1c
- 4 Optional, at the discretion of the investigator.
- 5 Only if occult blood, protein, or leukocytes present on dipstick analysis.
- 6 The spot urine sample should be a first-morning void.
- 7 If positive, HCV RNA levels should be measured. Participants with detectable HCV RNA will be excluded.
- 8 FSH for postmenopausal women at screening only.
- 9 Serum pregnancy test at Screening Visit 1 and urine pregnancy tests at other times as per the schedule in [Appendix 1](#) for women of childbearing potential only. Any positive urine pregnancy test will be confirmed by a serum pregnancy test.
- 10 Urine drug screen will be measured at Screening Visit 1. For all participants, the urine drug test should include, at a minimum, cotinine, amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, and cannabinoids.

## 6.12. Pregnancy Testing

All females of childbearing potential (as determined at screening) will have a serum pregnancy test during screening, and urine pregnancy tests for the duration of the study including follow-up as indicated in the Schedule of Assessments (Appendix 1). On Day 1, the urine pregnancy test must be done before dosing and must be negative to begin dosing.

Female participants of childbearing potential who require vaccinations (see Section 6.3) must also have a negative urine pregnancy test before any vaccine or booster is administered.

Any positive urine pregnancy test will be confirmed by a serum pregnancy test.

## 6.13. Sample Collection, Storage, and Shipping

### 6.13.1. Blood and Urine Collection for Complement Assays

Serum/plasma samples will be collected at the time points indicated in the Schedule of Assessments (Appendix 1). It is important that samples for PD testing be collected, prepared, and shipped in a way that ensures minimum freeze-thaw cycles and avoids potential in vitro complement activation before testing. Whole blood will be collected and processed to obtain cell-free serum or plasma which will be aliquotted into cryovials, frozen on dry ice, stored in a  $-80^{\circ}\text{C}$  freezer and shipped frozen to the designated laboratories for testing.

Urine samples will be collected at the time points indicated in the Schedule of Assessments (Appendix 1) and stored for potential assessment of the concentrations of selected complement proteins in urine.

Specific instructions for sample collection, processing, and shipping will be provided in a separate laboratory manual.

Biological samples, such as serum, plasma and urine, may be kept for up to 3 years after completion of the Clinical Study Report and then will be destroyed by internationally accepted means (e.g., incineration).

### 6.13.2. Blood Collection for Genetic Complement-Associated Biomarker Testing

Subject to participant consent, a sample will also be collected at screening for potential genetic analysis. Genetic analyses may be conducted if a participant does not respond to the investigative drug, to better understand a potential drug-related toxicity, or to further characterize the underlying disease. Genes which may be sequenced include (but are not limited to):

- Complement component C3
- Complement factor H-related proteins (CFHR1, CFHR3, CFHR4, CFHR5)
- Complement factor B
- Complement factor D
- Complement factor H
- Complement factor I
- Membrane Co-Factor Protein (MCP/CD46)
- Thrombomodulin (THBD)

All genetic samples will be stored for a maximum of 3 years after completion of the Clinical Study Report. During that time, samples may be retested if other mutations are discovered that may be associated with C3G. Participants may withdraw their consent for genetic testing and withdraw their samples from further genetic testing at any time by notifying the study investigator verbally and in writing. After the 3-year storage period defined above, or once the sponsor is informed of withdrawal of consent for further analysis, the sample will be destroyed consistent with accepted laboratory standards and no further testing or analysis will be completed. Any data already generated from the sample may continue to be used for the purposes of this study and future research.

### 6.13.3. Blood Volumes

Approximate blood volumes to be drawn are detailed in [Table 3](#) below. The maximum planned blood volume to be collected from each participant over the course of the study (approximately 143 weeks, including Screening, the 6-month Blinded Treatment Period, the 6-month Extended Treatment Period, Long-Term Follow-up Period, Taper, and Follow-up) is approximately 519 mL. The individual visit with the largest blood draws is expected to be the Screening visit (51 mL), and the maximum blood volume to be drawn in an 8-week window is 102 mL, from Day 1 to Week 8 (Day 56), inclusive. This does not include discarded blood from pre-collection used to flush catheters. The discarded volume is not expected to exceed 40 mL. Unanticipated additional blood may be collected throughout the study for such things as safety monitoring and additional PD assessments, if necessary, and if there are blood samples collected during any unscheduled visits.

**Table 3. Approximate Total Blood Volumes**

Period	Blood Volume (mL)						
	Screening	Treatment Periods			Taper	Follow-Up	Total
		Blinded (Weeks 1 to 28)	Extended (Weeks 29 to 52)	Long-Term (Weeks 53 to 143)			
TOTALS	51	190	65	139	37	37	519

The maximum volume drawn in an 8-week window is 102 mL, from Day 1 to Week 8 (Day 56), inclusive.

### 6.14. Dispensing Study Drug

ACH-0144471 will be supplied as 50 and 100 mg tablets. At each visit, the site will dispense study drug as required to provide participants with sufficient study drug for dosing until their next clinic visit. If a clinic visit is not possible during the COVID-19 pandemic, study drug will be sent directly to participant's home (Section 6.23).

### 6.15. Safety Assessments

Safety will be evaluated by monitoring and assessment of AEs, clinical laboratory tests, physical examination findings, and vital signs measurements at Screening, Baseline, and at various time points during the study as described in Section 7 and the Schedule of Assessments (Appendix 1).

### 6.16. Pharmacodynamic Assessments

PD markers monitor biological effects and are used in early drug development to assist in future decision making. Pharmacodynamics will be evaluated using serum, plasma, and urine collected during the study. Additional information on sample collection and shipping instructions will be provided in a separate laboratory manual.

Pharmacodynamics will be evaluated by assessment of Bb levels in plasma samples collected during the study, which should provide a direct readout of AP inhibition in vivo. In addition, the CP activity assay is a functional assay to qualitatively evaluate the effect of ACH-0144471 on total CP activity.

Inhibition of AP activity will also be evaluated with the AP Wieslab ELISA, AP hemolysis, and C3 convertase activity, the presence of autoantibodies to complement components or regulators, and the concentrations of multiple complement components and their split and terminal products in serum, plasma, and/or urine may be explored to understand their association with the underlying disease and any changes in response to ACH-0144471 treatment.

White blood cells will be collected and stored for possible genetic profiling of selected complement components and regulators (see Section 6.13.2) for possible exploration of the understanding of the underlining etiology of C3G and any correlation with participants' response to ACH-0144471.

## **6.17. Patient-Reported Outcomes Assessments**

### **6.17.1. Quality of Life Questionnaires**

All participants enrolled in the trial will self-administer questionnaires for the FACIT-Fatigue (version 4), KDQOL version 1.3, and EQ-5D-3L scales at the times specified in [Appendix 1](#) to assess their HRQOL, fatigue, and kidney-related fears and worries (e.g., kidney failure, dialysis, kidney transplant), and to determine health states value, over the course of treatment with ACH-0144471. Local language versions of each of the tools will be provided separately.

## **6.18. Adverse Events Assessments**

### **6.18.1. Definitions**

Adverse events (AEs) must be assessed for the investigational products in this study. An investigational product is defined as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in the study, whether blinded or unblinded. The term “adverse event” is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can arise with any use of the drug (e.g., off-label use, use in combination with another drug) and with any route of administration, formulation, or dose, including an overdose.

Medical occurrences, including pregnancies, that begin before the start of study intervention but after obtaining informed consent will be recorded on the Medical History/Current Medical Conditions section of the CRF, not the AE section. This does not include pre- or post-treatment complications that occur as a result of protocol-mandated procedures (e.g., invasive procedures, such as venipuncture or biopsy), which should be reported as AEs. While pregnancy itself is not considered an AE, for the purposes of tracking, a pregnancy occurring after the start of study intervention should be captured as an AE as well as reported on the pregnancy forms.

A treatment-emergent adverse event (TEAE) is defined as an AE that emerges during treatment, having been absent prior to treatment, or worsens relative to the pretreatment state. In this study, any AE first assessed after receipt of the first dose of ACH-0144471 until 28 days after the last dose of study drug will be considered treatment-emergent, as defined in Section [6.18.5](#). All TEAEs will be recorded and reported.

An AE (including a TEAE) can be one or more of the following:

- Any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, and does not imply any judgment about causality.
- Any new disease or exacerbation of an existing disease.
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline.
- Any case of abuse of alcohol, illicit drugs, or prescription drugs; abuse of study drug(s) or protocol-specified drug(s); addiction.
- A pregnancy that occurs or becomes confirmed during a clinical study (see Section [6.18.8](#)).

- Laboratory test or other clinical test (e.g., ECG or X-ray) with a clinically significant abnormality (as defined below).
- An effect of the study medication, including comparator.
- Any dose of medication (study drug or other concomitant medication) that is taken at a dose higher than the prescribed dose (i.e., an overdose). Overdose should be reported as an AE whether or not it is associated with any symptoms or signs.

The following are not considered to be AEs:

- Medical or surgical procedures (e.g., surgery, endoscopies, tooth extraction, transfusion, etc.) - the condition which leads to the procedure is the AE;
- Preexisting diseases or conditions or laboratory abnormalities present or detected prior to the screening evaluation that do not worsen;
- Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for elective surgery, social and/or convenience admissions, etc.)

Clinically significant changes in objective findings (e.g., laboratory, ECG, physical examination) should be considered AEs only if they meet one or more of the following criteria:

- Associated with accompanying symptoms;
- Require medical/surgical intervention;
- Lead to a change in study drug dosing or discontinuation from the study;
- Lead to significant additional concomitant drug treatment, or other therapy;
- Lead to any of the outcomes included in the definition of a serious adverse event;
- Are considered clinically significant by the investigator.

Whenever possible, the etiology of the abnormal finding (rather than the abnormal finding itself) should be documented as the adverse event. Repeated additional tests and/or other evaluations required to establish the significance and etiology of an abnormal result should be obtained when clinically indicated.

Any abnormal test result that is determined to be an error does not require reporting as an AE.

Surgical procedures themselves are not AEs but are therapeutic measures for conditions that require surgery. The condition for which the surgery is required may be an adverse event, if it occurs or is detected during the study period. Planned surgical measures permitted by the clinical study protocol (if any) and the condition(s) leading to these measures are not AEs, if the condition(s) was (were) known before the start of the study treatment and documented in the participant's medical record. In the latter case, the condition should be reported as medical history.

All participants who have AEs, whether considered to be associated with the use of the investigational product or not, must be monitored to determine the outcome of the event(s). The clinical course of the AE will be followed according to accepted standards of medical practice, even after the end of the period of observation, until a satisfactory explanation is found, or the investigator considers it medically justifiable to terminate follow-up.

#### **6.18.2. Criteria for Assessing Seriousness**

All AEs must be evaluated as potential SAEs. If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met. An SAE is any untoward medical occurrence that occurs at any dose and meets at least one of the following criteria:

- Results in death
- Is life-threatening i.e., the participant was at immediate risk of death from the AE as it occurred. (This does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death.)
- Requires inpatient hospitalization or prolongation of existing hospitalization for the AE
  - The following types of hospitalizations are not considered SAEs for regulatory reporting purposes:
    - Hospitalization(s) for planned (pre-scheduled) medical procedures known at the time of screening
    - Protocol-specific hospital admission
    - Respite care
    - Admission for the treatment of pre-existing condition (known at the time of screening) not associated with the development of a new AE or with the worsening of the pre-existing condition
    - Observation/same day/ambulatory procedure
- Is a persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions
- Is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug)
- Is an important medical event or reaction

#### **6.18.3. Documentation and Reporting of Adverse Events**

AEs, including TEAEs, may be spontaneously reported by a participant or his/her representative, or elicited during questioning and examination of a participant. All AEs will be assessed by the Investigator and documented regardless of apparent causality from use of the study treatment(s). For each AE, the investigator will evaluate and report the date of onset and resolution, outcome, severity, relationship to study treatment(s), action taken, additional treatments required to manage the event, and determination of seriousness. All identified AEs occurring during the trial and follow-up period must be fully recorded and described on the appropriate CRF page. The AE

should be reported in standard medical terminology. Whenever possible, the AE should be evaluated and reported as a diagnosis, rather than as individual signs or symptoms. A cluster of signs and symptoms that results from a single cause should be reported as a single AE (e.g., fever, elevated WBC, cough, abnormal chest X-ray, etc. can all be reported as “pneumonia”).

If a definitive diagnosis is not possible, the individual symptoms and signs should be recorded. Documentation must be supported by an entry in the participant’s medical record. The relationship to study drug or study procedures should be assessed using the definitions in Section 6.18.7.

#### **6.18.4. Treatment and Follow-Up of Adverse Events**

All AEs should be followed up (including obtaining relevant laboratory tests) until they have returned to baseline status or stabilized. If a clear explanation is established, it should be recorded. Follow-up of AEs will continue through the last day on study (including the follow-up period) or until the events have resolved or stabilized to the satisfaction of the PI and the Achillion Pharmaceuticals Medical Monitor (or designee). Achillion Pharmaceuticals may request that certain AEs be followed until resolution or stabilization.

#### **6.18.5. Timeframe for Collection of Adverse Events**

AEs include events that have appeared or worsened during the course of the clinical trial. AEs may also include pre- or post-treatment complications that occur as a result of protocol-mandated procedures (e.g., invasive procedures, such as venipuncture, biopsy, etc.).

Any AE (i.e., a new event or an exacerbation of a preexisting condition) with an onset date after the participant provides informed consent through the 28 days following the participant’s last study drug dose will be recorded as an AE on the appropriate CRF page(s).

All SAEs, regardless of cause or relationship, occurring within 28 days of last study drug dose must be documented and reported.

Follow-up of SAEs will continue through the last day on study or until the event has resolved or stabilized to the satisfaction of the PI and the Achillion Pharmaceuticals Medical Monitor (or designee). Investigators are not obligated to actively seek out SAEs beyond the follow-up period. However, if the PI (or designee) learns of an SAE occurring after completion of the final follow-up visit, and the SAE is deemed by the PI (or designee) to be related to the study drug (s), the PI (or designee) should promptly document and report the event to Achillion Pharmaceuticals.

#### **6.18.6. Severity and Grading of Adverse Events**

The severity of an adverse event will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 [36]. The PI (or designee) should determine the severity of the AE (mild, moderate or severe) based on the overall clinical importance or significance of the finding for that individual participant.

If an AE that was reported during the study increases or decreases in severity, then that AE is given a resolution date and time and a new record initiated with the new severity. If the severity of an AE remains the same, the AE will be kept open through to resolution.



### 6.18.7. Assessment of Causality

The investigator must assess the likelihood that the study drug caused or contributed to each AE, and document this assessment assigning one of the following relatedness criteria to each AE:

- **Unrelated:** In the opinion of the investigator, there is no association between the study drug and the AE.
- **Unlikely:** In the opinion of the investigator, it is unlikely that there is an association between the study drug and the reported event.
- **Possible:** In the opinion of the investigator, treatment with the study drug may have caused or contributed to the AE but could also have been produced by other factors (i.e., the event follows a reasonable temporal sequence from the time of drug administration and/or follows a known response pattern to the study drug, but is also known to be caused by other factors).
- **Probable:** In the opinion of the investigator, it is likely that the study drug caused or contributed to the AE based on a reasonable temporal sequence of the event with drug administration and, the known pharmacologic action and/or adverse reactions of the drug (or class of drugs) or the investigator's clinical judgment.
- **Definite:** In the opinion of the investigator, it is definite that the study drug caused or contributed to an AE, and other conditions (e.g., concurrent illness, progression/expression of disease state, or concurrent medication reaction) do not explain the event.

For the purposes of determining expedited reporting status to Health Authorities, Achillion considers the assessments of 'unrelated' and 'unlikely' as unrelated to study drug and 'possible', 'probable', and 'definite' as related to study drug.

In addition, for any analyses of AE data in which only two categories of 'related' and 'unrelated' are used, the assessments of 'unrelated' and 'unlikely' will be combined into the category of 'unrelated', and the assessments of 'possible' and 'probable' and 'definite' will be combined into the category of 'related'.

### 6.18.8. Pregnancy

Any pregnancy, including in a female partner of a male participant, that occurs or becomes confirmed during a clinical study (time frames outlined in Section 6.18.5) must be reported to Achillion (or designee) within one business day of first knowledge of the pregnancy. The report should be provided on the pregnancy form. While pregnancy itself is not considered an AE, for the purposes of tracking, it should be captured as an AE as well as reported on the pregnancy forms.

All pregnancies temporally related to study drug should be followed and discussed with the medical monitor as follows:

- The investigator will follow up with the participant or the participant's female partner approximately every 3 months throughout the pregnancy and report to Achillion (or designee) using the pregnancy forms. Generally, follow up will not be required for longer than 6-8 weeks beyond the estimated delivery date.



- The investigator will report any information on the status of the pregnancy to Achillion (or designee) using the pregnancy forms.
- The outcome of the pregnancy will be reported to Achillion (or designee) using the pregnancy forms. Any termination of pregnancy will be reported, regardless of fetal status (i.e., presence or absence of anomalies) or indication for the procedure.

Any SAEs related to the pregnancy (see below), or occurring during the participant's pregnancy, or after delivery, must be documented and reported to Achillion (or designee) on both the SAE Form and the pregnancy forms. SAEs occurring in the child (e.g., congenital anomalies or other conditions present at birth, whether genetically inherited or occurring in utero) must also be documented on both the SAE form and the pregnancy forms.

Reportable SAEs associated with pregnancy include, but are not limited to:

- Pregnancy losses (e.g., spontaneous abortion, late fetal death, elective termination)
- Life-threatening developments (e.g., placental abruption, fetal distress)
- Congenital anomalies
- Neonatal or maternal death, or
- Any event resulting in maternal or neonatal hospitalization/prolonged hospitalization.

#### **6.18.9. Reporting Serious Adverse Events**

Achillion Pharmaceuticals has requirements for the expedited reporting of safety events meeting specific requirements to worldwide regulatory authorities; therefore, Achillion Pharmaceuticals must be notified immediately regarding the occurrence of any SAE and/or pregnancy that occurs during the study (time frames outlined in Section [6.18.5](#)).

The procedures for reporting all SAEs and/or pregnancies, regardless of causal relationship, are as follows:


##### **SAE**

- Record the SAE within 24 hours of becoming aware of the event by logging into the EDC system (Fusion) and completing an initial SAE report.
- This will trigger an email notification to the Axiom and Achillion Pharmaceuticals distribution lists.

##### **Pregnancy**

- Record the pregnancy into the EDC system (Fusion) and completing the pregnancy form.
- This will trigger an email notification to the Axiom and Achillion Pharmaceuticals distribution lists.

Contact information is provided below.

<b>SAE CONTACT</b>
<b><u>SAE Telephone Number:</u></b> In the event of <b>System failure</b> , or for questions about completing the forms in EDC:  <b>Axiom Real-Time Metrics</b> PPD 

For fatal or life-threatening events, provide copies of hospital discharge reports, autopsy reports, and other documents, as applicable. Achillion Pharmaceuticals may request additional information from the PI to ensure the timely completion of accurate safety reports.

In the case of a medical emergency, please use the contact provided on the title page of the protocol.

#### **6.18.10. Investigator Reporting Requirements for SAEs**

Achillion is responsible for ensuring that Investigators and central ECs/IRBs are notified of all AEs that are serious, unexpected and considered related, probably related, or possibly related to the investigational product. A CRO may be designated to perform this notification. This notification will be in the form of a MedWatch/CIOMS report. The PI will notify the local ECs or IRBs as per EC or IRB requirements. Upon receiving such notices, the PI must review and retain the notice. The Sponsor, investigator, and EC or IRB will determine if the informed consent requires revision. The PI should also comply with EC or IRB procedures for reporting any other safety information.

#### **6.19. Concomitant Medication Assessments**

Details of all prior (within 90 days of the screening evaluation) and concomitant medication use, including all medications administered for the treatment of AEs, will be recorded in the participant's CRF at each study visit.

#### **6.20. Monitoring Participant Safety**

The safety of participants will be monitored by Investigators and by a medical monitor (or designee) at Achillion Pharmaceuticals on an ongoing basis while participants are receiving ACH-0144471. A Fever Management Plan ([Appendix 2](#)) has been developed for this study to enable rapid assessment, detection and treatment of any potential serious infection.

#### **6.21. Removal of Participants from the Trial or Study Drug**

A participant is free to withdraw from the study at any time without jeopardizing future medical care. The PI (or designee) may decide, for reasons of medical prudence or participant noncompliance, to discontinue dosing in a participant. The PI should also stop dosing in any participant who meets an individual stopping rule (Section [3.2.3.2](#)). In either case, whenever possible, the Achillion MM should be notified immediately, and if possible, before dosing is terminated.

If dosing is to be terminated, it may be done so immediately, or a taper can be implemented as described in Section 5.2.1, whichever is considered to be in the best interest of the participant. When dosing is terminated, study participation is not necessarily immediately terminated. Instead, whenever possible, the participant should complete all activities in the Taper and Follow-Up periods (if tapered) or in the Follow-Up period (if discontinued immediately), as described in Appendix 1.

Reasons for participant withdrawal include (but are not limited to):

- One or more of the stopping criteria described in Section 3.2.3 is met
- Intercurrent illness that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree
- Unacceptable toxicity (including a clinically significant laboratory abnormality) necessitating discontinuation of study or that, in the judgment of the investigator, compromises the ability to continue study-specific procedures, or it is considered not to be in the participant's best interest to continue the study
- Participant request to discontinue for any reason
- A female participant becomes pregnant or wishes to become pregnant
- Participant noncompliance
- Discontinuation of the study at the request of Achillion Pharmaceuticals, regulatory agency, or Ethics Committee or IRB
- Any other condition or circumstance that would jeopardize the welfare of the participant if s/he were to continue in the trial

The reason for any participant's discontinuation and the date of withdrawal will be recorded in the participant's CRF. The participant's CRF, which will be completed up to the point of withdrawal, will be retained for the Sponsor.

## **6.22. Study Assessments When Clinic Visits are Not Possible due to the COVID-19 Pandemic**

If a study participant is unable to get to a clinic visit, study data collection may still occur:

### **Option 1 (preferred option)**

- **Home Healthcare Visits:** At these home visits, nurses may collect 24-hour urine, first morning urine, and safety labs, including pregnancy testing, for shipment to the central laboratory. Serum/plasma biomarker laboratory assessments, and serum C3 and C4 assessments cannot be collected at home visits, due to the stringent storage and handling requirements of these specimens. Other assessments will include adverse events, vital signs, concomitant medications, and study drug accountability. Physical examinations, weights, and patient-reported outcomes will not be collected at home health visits.

**Option 2 (if Option 1 is not possible)**

- **Telephone visits:** If home visits are not possible, participants may have telephone visits with the PI or designee. Data collection should include adverse events and concomitant medications. Physical examinations cannot be performed during a telephone visit. Patients will be asked about study drug compliance.
  - **Local Laboratories:** If home visits are not possible, the participant should go to a local laboratory to drop off 24-hour urine collections and for safety laboratory testing, including pregnancy testing (if applicable), to be performed.

**6.23. Study Drug Compliance and Supply When Clinic Visits are Not Possible**

If a study participant is unable to get to a clinic visit during the COVID-19 global pandemic, study drug may be shipped to the participant's home.

Treatment compliance assessments shall be made at each home visit or telephone visit. Participants will be asked about their supply of study drug so that study drug compliance may be assessed. Study staff will address any non-compliance issues with the participant.

**6.24. Renal Biopsies When Clinic Visits are Not Possible**

If a study participant is unable to get to a clinic visit during the COVID-19 global pandemic, optional renal biopsies at Week 52 and Week 104 should be performed when possible, even if the biopsy is done outside the visit window of  $\pm 7$  days. In addition, an unscheduled 24-hour urine collection should be obtained at the same time as the optional biopsies at Week 52 and Week 104. If the collection of 24-hour urine is to occur after a renal biopsy, it must be done at least 7 days after the biopsy procedure.

## 7. STUDY ACTIVITIES

Activities for each visit are provided in the Schedule of Assessments ([Appendix 1](#)). Additional details for the various activities are provided in Section 6.

During the periods when multiple assessments occur at the same time, ECGs and vital signs should be recorded prior to blood sampling.

The actual times of procedures and sample collections will be recorded in the participant's CRF.

### 7.1. Screening Period (Days -75 to -1)

For each participant, informed consent or assent will be obtained as described in Section 6.1 before the participant enters into the study and any study-related procedures are performed. Participant eligibility will be determined according to the criteria specified in this protocol. All screening eligibility assessments listed in the Schedule of Assessments ([Appendix 1](#)) should be performed and documented prior to dosing. This should include a review of the inclusion and exclusion criteria, and a review of the study restrictions, as defined in Section 5.5. The participant's medical history should be reviewed as described in Section 6.2, and a complete physical examination should be conducted as described in Section 6.7. A 24-hour urine sample should be collected as described in Section 6.6.1 and a first morning urine sample should be collected as described in Section 6.6.2; participants may be provided with collection containers and may bring their samples to the clinic.

If the participant remains eligible, then arrangements can be made for any required vaccinations (see Section 7.1.2). If required, vaccinations should be at least 2 weeks before the first dose of study drug unless otherwise recommended by national and/or local guidelines or local clinical practice. Participants who meet all eligibility criteria will be educated about the restrictions on concomitant medication usage and other substances.

Each adult participant will complete the KDQOL-SF v1.3, FACIT-Fatigue, and EQ-5D-3L questionnaires during the screening period, prior to study treatment administration.

All evaluations required for determination of eligibility must be completed before the participant is randomized into the study.

If the participant is unable to receive study drug within 75 days of screening the participant may be re-screened once (for all assessments except the renal biopsy).

The repeating of individual screening laboratory results that fall outside the protocol-required range may be permitted on a case-by-case basis with the written pre-approval of the Achillion Pharmaceuticals Medical Monitor (or designee).

#### 7.1.1. Screening and Pre-Treatment Renal Biopsy

If necessary to confirm eligibility (as discussed in Section 6.3.1) or as a pre-treatment (baseline) biopsy a renal biopsy should be performed during screening according to the procedures described in Section 6.3. When obtained to confirm eligibility, the results must be available and reviewed prior to dosing. Given that the renal biopsy is an invasive procedure, a participant should be confirmed as eligible by all other criteria before the renal biopsy is performed.

Biopsies will not be obtained from participants less than 18 years of age (unless they are determined to be clinically indicated by the treating provider), or from participants for whom a biopsy is contraindicated.

### **7.1.2. Vaccination**

As part of the screening process, participants will be evaluated to determine whether vaccination against *N. meningitidis*, *S. pneumoniae*, or *H. influenzae* is to be performed, as described in Section 6.3. Female participants of childbearing potential must have a negative urine pregnancy test on the day of vaccination, before any vaccine or booster is administered.

## **7.2. Blinded Treatment Period**

During the Blinded Treatment Period, physical examinations, assessment of vital signs, all required safety laboratory testing, and collection of blood and urine samples for PD evaluation will be performed at various time points as specified in [Appendix 1](#).

Participants should be instructed to fast prior to coming to a clinic visit; however, they may drink water or other non-alcoholic beverages. Participants should be instructed to bring their study drug with them for administration at the site.

At clinic visits, participants should be instructed how to take their medication at home, as described in Section 5.3, and record the time they took it.

Participants should be instructed to store their study drug at room temperature, as described in Section 5.8.

In-clinic visits will be scheduled as listed in the Schedule of Assessments (Appendix 1). The final visit in the Blinded Treatment Period will be at Week 28.

The assessments listed in the Schedule of Assessments (Appendix 1) should be performed prior to the administration of the first daily dose of study drug.

As indicated in the Schedule of Assessments (Appendix 1), participants will be asked to complete the QoL assessments at Week 28. Each adult participant will be asked to complete the KDQOL-SF v1.3 questionnaire, the FACIT-Fatigue scale, and the EQ-5D-3L.

The visits on Weeks 3, 5, 6, 7, 10, 14, 18, 22, 24, 26, 32, 40, and 48 can be conducted by phone

## **7.3. Extended Treatment Period**

During the Extended Treatment Period, physical examinations, assessment of vital signs, and all required safety laboratory testing, and collection of blood and urine samples PD evaluation will be performed at various time points as specified in Appendix 1.

Participants should bring their study drug with them for administration at the site.

At clinic visits, participants should be instructed how to take their medication at home, as described in Section 5.3, and record the time they took it.

Participants should be instructed to store their study drug at room temperature, as described in Section 5.8.

As listed in the Schedule of Assessments ([Appendix 1](#)), outpatient clinic visits will be scheduled on Weeks 29, 30, 32, 36, 44, and 52. Visits at Week 40 and 48 can be done by phone call. Some participants will be transitioning from placebo to ACH-0144471 after Week 28, and investigators and participants may not know the treatment assignments due to the study being blind. The assessments listed in the Schedule of Assessments ([Appendix 1](#)), including measurement of the listed complement markers should be performed prior to the administration of the first daily dose.

As indicated in the Schedule of Assessments ([Appendix 1](#)), participants will be asked to complete the QoL assessments at Week 52. Each adult participant will be asked to complete KDQOL-SF v1.3 questionnaire, EQ-5D-3L, and the FACIT-Fatigue scale.

#### **7.4. 21- Month Long-Term Follow-up**

During the 21-Month Long-Term Follow-up Period, quarterly visits will be completed in clinic. The visits will include physical examinations, assessment of vital signs, all required safety laboratory testing, and collection of blood and urine samples and complement biomarker evaluation to be performed as specified in [Appendix 1](#).

Participants should bring their study drug with them for administration at the site.

At clinic visits, participants should be instructed how to take their medication at home, as described in [Section 5.3](#).

Participants should be instructed to store their study drug at room temperature, as described in [Section 5.8](#).

#### **7.5. Taper Period**

It is recommended that participants who discontinue ACH-0144471 have study drug tapered over 3-6 days, as described in [Section 5.2](#). If a participant meets an Individual Stopping Rule ([Section 3.2.3.2](#)) and dosing is stopped, the PI should consider whether it is in the best interest of the participant to discontinue dosing immediately or to taper (as described in [Section 5.2.1](#)). Whenever possible, the taper decision should also be discussed with the Achillion MM prior to dosing termination. If a Group Stopping Rule is met and dosing is terminated in the study, the Achillion MM in consultation with the PI will decide whether or not the taper should be implemented. When dosing is terminated, study participation is not necessarily immediately terminated. Instead, whenever possible, the participant should advance to the Taper and/or Follow-Up Periods, as relevant, and complete all activities in those periods as described in [Appendix 1](#). Participants who are completing the taper will have assessments indicated in [Appendix 1](#) performed on Days 3 (T3) and 6 (T6) of the taper period.

Participants will be instructed to bring their study drug with them for administration at the site. Participants will continue taking their medication at home in the same way as previously described (see [Section 5.2](#)).

Participants will be instructed to store their study drug at room temperature, as described in [Section 5.8](#).



Participants should be instructed how to take their medication at home, as described in Section 5.3, and record the time they took it.

## 7.6. Follow-Up Period

During the Follow-Up Period, physical examinations, assessment of vital signs, all required safety laboratory testing, and collection of blood and urine samples for PD evaluation will be performed at various time points as specified in [Appendix 1](#).

As listed in the Schedule of Assessments (Appendix 1), participants will be evaluated at the clinical site 2 weeks after the last dose of study drug, and again 4 weeks after the last dose of study drug during the Follow-up Period. Participants should arrive at the clinic at the time designated by site personnel. If necessary, clinic visits during the Follow-Up Period may occur up to 2 days earlier or later than scheduled. Unless the PI feels a clinic visit is required, the 4-week follow up may be conducted by a phone call

## 7.7. Early Termination from the Study

A participant who discontinues dosing does not necessarily discontinue from the protocol, and whenever possible, should continue with the Taper and/or Follow-Up Periods, as relevant, and complete all activities in those periods as described in Appendix 1. If this is not possible, a participant who withdraws from this study should at a minimum have the assessments listed for the second follow up visit in the Schedule of Assessments (Appendix 1).

## 7.8. Unscheduled Visits

Additional clinic visits may be added if deemed necessary by the Investigator. Activities at these visits will be directed by the circumstances, but should include at a minimum:

- Assess for compliance with protocol restrictions
- Assess for AEs and SAEs
- Record concomitant medications
- Measure body temperature
- Additional tests or procedures as appropriate

The reason for the visit and the results of any tests or procedures must be recorded in the participant's CRF.



## **8. QUALITY CONTROL AND ASSURANCE**

### **8.1. Routine Monitoring**

The PI is responsible for the validity of all data collected at the clinical site and must accept the various monitoring procedures employed by the Sponsor. The purpose of monitoring is to verify that the rights and well-being of human participants are protected; that trial data are accurate, complete, and verifiable with source data; that the trial is conducted in compliance with the protocol, GCP, and the applicable regulatory requirements.

A monitor assigned by the Sponsor will conduct regular site visits for the purpose of monitoring various aspects of the study. Visits will take place usually within a predetermined interval, but this may vary during the course of the study. The PI must agree to allow the study monitor and authorized representatives of the Sponsor to inspect all CRFs and corresponding source documents, e.g., original medical records, participant records and laboratory raw data, access to the clinical supplies, dispensing, and storage areas and agree to assist with their activities if requested. The PI should provide adequate time and space for monitoring visits.

The monitor will query any missing or spurious data with the PI (or designee), which should be resolved in a timely manner. A monitoring log will be maintained recording each visit, the reason for the visit, the monitor's signature, and PI or designee's confirmation signature.

### **8.2. Site Audits**

For the purpose of compliance with GCP and regulatory agency guidelines, it may be necessary for Sponsor authorized Quality Assurance personnel and/or authorized personnel from an external regulatory agency to conduct an audit/inspection of an investigational site. The purpose of an audit is to assess the quality of data with regard to accuracy, adequacy, and consistency, and to assure that studies are in accordance with GCP, and Regulatory Agency guidelines. Having the highest quality data from studies is an essential aspect of drug development.

The PI will be given sufficient notice to prepare for such visits, which are planned to take usually between one and two days and may be conducted at any stage during the study. The audit will involve the review of all study related documentation, which is required by GCP to be maintained by each site, review of drug storage, dispensing, and return, review of all study related supplies and review of source documents against the CRFs to assure the adequacy and accuracy of the information that has been recorded, including the verification of any AEs that have occurred.

In the event of the site being notified of a regulatory inspection, the Sponsor will help with the preparation and it is essential that they be notified of the inspection as soon as possible.

## **9. PLANNED STATISTICAL METHODS**

### **9.1. General Considerations**

The planned statistical analysis methodologies will apply to the data collected both during Blinded Treatment Period and open-label Extended Treatment Period, wherever appropriate.

Summary statistics will be provided for efficacy and safety parameters by the treatment group, ACH-0144471 and placebo.

To summarize continuous data, descriptive statistics will include: number of participants, mean, standard deviation, median, minimum, and maximum. To summarize categorical data, frequency counts and percentages will be presented.

Longitudinal summaries of efficacy and safety parameters use pre-defined visit week as described in [Appendix 1](#), Schedule of Assessments. Laboratory measures will be summarized using standard values and units.

Participant listings will be provided for all efficacy (including PD) and safety parameters.

A statistical analysis plan (SAP) will be developed and finalized prior to database lock. The SAP will provide details of the data analysis procedures and presentations, including relevant subgroup analysis. Analysis procedures for addressing exploratory objectives, including those based on QoL measures, will also be included in the SAP.

### **9.2. Determination of Sample Size**

The sample size is determined based on limited clinical cases of C3G to evaluate the effectiveness of ACH-0144471.

### **9.3. Analysis Populations**

All participants receiving at least one dose of study drug, ACH-0144471 or placebo, will be included in the efficacy, safety, and pharmacodynamic analyses.

### **9.4. Demographics and Baseline Characteristics**

The following will be summarized by treatment group and overall for treated participants:

- demographics: age, gender, race, country / geographic region
- disease characteristics at baseline: disease diagnosis, duration of the disease, biopsy results
- physical measurement at baseline: height, weight, BMI
- laboratory tests at baseline
- prior medications.

Additional baseline characteristics may also be summarized as clinically indicated.

## 9.5. Efficacy, including Pharmacodynamics Analysis

The primary efficacy endpoint is:

- Change from baseline in biopsy, based on a score incorporating changes in both the activity index and C3 staining at the end of 6 months of treatment.
- Number and percent of participants with reduction in proteinuria relative to baseline at the end of 6 months of treatment

The secondary efficacy endpoints are:

- Change and percent change from baseline in proteinuria over 6 months of treatment
- Change and percent change from baseline in eGFR over 6 months of treatment
- Number and percent of participants with significant improvement relative to baseline in eGFR at the end of 6 months of treatment.
- Descriptive analysis of slope of GFR from baseline to 6 months
- Descriptive analysis of slope of GFR after 12 months of ACH-0144471 therapy

eGFR will be provided using the following formulas:

- For participants 19 years old and older the CKD-EPI creatinine equation (2009) will be used for inclusion/exclusion and primary endpoint analysis. However, cystatin C will also be measured and as exploratory analysis, eGFR will be calculated by the CKD-EPI creatinine-cystatin equation (2012), the CKD-EPI cystatin C equation (2012), and the MDRD equation.
- For participants <19 years old the creatinine-based “Bedside Schwartz” equation (2009) will be used for inclusion/exclusion and primary endpoint analysis. However, cystatin C will also be measured and as exploratory analyses, eGFR will be calculated by the cystatin C-based equation (2012) and the creatinine-cystatin C-based CKiD equation (2012)

Cystatin C will be measured to allow use of formulas requiring this parameter. Note that calculation details of eGFR will be in detail in the laboratory manual.

When possible, proteinuria will be evaluated in 24-hour urine collections, but if a 24-hour urine is not available, a calculated equivalent will be derived from albumin:creatinine and/or total protein:creatinine ratios, obtained from spot urine samples. The process for deriving this calculated equivalent will be described in detail in the laboratory manual.

For changes and percent changes at end of 6 months of treatment, 95% confidence intervals will be provided for the mean differences between ACH-0144471 and placebo. Fisher’s Exact statistics will be used to compare the two treatment groups for the categorical efficacy parameters / response rates.

## 9.6. Safety Analysis

Treatment-emergent AEs (TEAEs) will be summarized and listed by system-organ-class and preferred term using the most current version of the Medical Dictionary for Regulatory Activities (MedDRA<sup>®</sup>). All SAEs and discontinuation due to AEs will be listed in tabulated format.

All clinical laboratory data (hematology, serum chemistry, and urinalysis) with normal ranges, out-of-range flags, and toxicity grades will be listed by participant. Descriptive summary statistics may be provided for selected lab tests.

Data on physical exam, vital signs, and ECG will be examined either through participant listings or by summary statistics of selected parameters.

Other exploratory techniques, e.g., graphic presentations, may also be employed to facilitate clinical interpretations of the safety results.

## **10. ADMINISTRATIVE CONSIDERATIONS**

### **10.1. Investigators and Study Administrative Structure**

The PI must maintain a screening log of all participants seen and considered for the study. For those participants who are not eligible to participate in the study, the reason for their exclusion should be recorded.

### **10.2. Institutional Review Board (IRB) or Independent Ethics Committee (IEC) and Regulatory Approval**

#### **10.2.1. Ethical Approval**

The study protocol, participant information and consent and assent forms, the Investigator Brochure, available safety information, participant recruitment procedures (e.g., advertisements), information about payments and compensation available to the participants and documentation evidencing the investigator's qualifications should be submitted by the investigator to the EC or IRB for ethical review and approval according to local regulations, prior to the start of the study. The written approval should identify all documents reviewed by name, version, and the date on which the committee met and granted the approval.

Any modifications to EC or IRB approved documents must also be submitted to the EC or IRB for approval before implementation.

#### **10.2.2. Regulatory Approval**

As required by local regulations, the Sponsor's (or designee's) Regulatory Affairs group will ensure all legal aspects are covered, and approval of the appropriate regulatory bodies obtained, prior to study initiation.

#### **10.2.3. Amendments**

Any change to the protocol will be affected by means of a protocol amendment. Any changes, which affect participant safety or welfare, will be submitted to the EC or IRB and regulatory authority (where applicable) for approval prior to implementation. The investigator, EC, and Sponsor must agree on all amendments. No amendment will be implemented until it is approved and signed by the investigator and Sponsor. Exceptions to this are when the investigator considers that the participant's safety is compromised. Protocol amendments detailing minor administrative changes should be submitted by the investigator (or designee) to the EC or IRB for notification.

### **10.3. Ethical Conduct of the Study**

This study will be performed in accordance with: 1) the principles of ICH Guideline E6 for Good Clinical Practice (CPMP/ICH/135/95 January 1997); 2) European Directive 2001/20/EC, 3) standard operating procedures and/or guidelines, 4) the U.S. Food and Drug Administration (FDA) regulations, 5) the Declaration of Helsinki, and 6) all applicable federal, state, and local laws, rules and regulations relating to the conduct of the clinical study.

## **10.4. Participant Information and Consent**

In obtaining and documenting informed consent or assent, the investigator should comply with the applicable regulatory requirements and should adhere to ICH GCP (E6). Each participant must be adequately informed in a language that they can understand and read of the aims, methods, anticipated benefits, potential hazards and the discomfort the study may entail, as well as their right to abstain from participating in the study and to withdraw their consent at any time without affecting their medical care. If important new information is incorporated in the ICF and approved by the EC, all participants still actively participating in the study must be re-consented.

Written informed consent for adult participants should be documented by the participant's personally dated signature and the personally dated signature of the investigator or designee who conducted the informed consent discussion. The investigator or designee should supply all enrolled participants with a copy of their signed informed consent. The monitor will inspect the original forms for all participants.

## **10.5. Participant Confidentiality**

The investigators and Sponsor and its designees will preserve the confidentiality of all participants taking part in the study, in accordance with GCP, local regulations and, to the extent applicable, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). Subject to the requirement for source data verification by the study personnel by reference to the participant's notes, confidentiality of all participant identities will be maintained. Only participant initials, date of birth, and study number will be used on the CRF and in all study correspondence, as permitted. No material bearing a participant's name will be kept on file by the Sponsor.

## **10.6. Study Monitoring**

### **10.6.1. Access to Information for Monitoring**

In accordance with ICH-GCP guidelines, the Study Monitor must have direct access to the investigator's source documentation in order to verify the consistency of the data recorded in the CRFs.

The Study Monitor is responsible for routine review of the CRFs at regular intervals throughout the study, to verify adherence to the protocol, and the completeness, consistency, and accuracy of the data being entered. The Study monitor should have access to any participant records needed to verify the entries on the CRFs. The investigator agrees to cooperate with the Study Monitor to ensure that any problems detected in the course of these monitoring visits are resolved.

### **10.6.2. Access to Information for Auditing or Inspections**

Representatives of regulatory authorities or Achillion Pharmaceuticals may conduct inspections or audits of the clinical study. If the investigator is notified of an inspection by a regulatory authority, the investigator agrees to notify the Achillion Pharmaceuticals Medical Monitor immediately. The investigator agrees to provide to representatives of a regulatory agency or Achillion Pharmaceuticals access to records, facilities, and personnel for the effective conduct of any inspection or audit.

## **10.7. Case Report Forms and Study Records**

### **10.7.1. Recording of Data**

All data collected during the study will be recorded in individual, participant-specific electronic case report forms (eCRFs). All eCRFs should be completed by the investigator (or designee), who should be identified and agreed upon with the Sponsor before the start of the study. A signature log identifying personnel who can enter data and/or sign off an eCRF will be maintained. Instructions for data entry will be provided.

A CRF must be completed for each participant who signs a consent form and is admitted to the study. Corrections to the data on the CRF will only be made by the investigator (or designee).

CRFs should be kept current to enable the study monitor to review the participant status throughout the course of the study. CRFs will be completed within 5 days of the last participant visit.

### **10.7.2. Source Documentation and Medical/Study Records**

The participant's number and date of entry into the study, along with the study code, should be recorded in the participant's medical/study records by the investigator (or designee). The investigator (or designee) should also record, in the medical/study records, confirmation of written and oral consent, the participant's clinical status/disease being treated, date of every study visit, date study drug started and stopped, concomitant medications, copies of all relevant reports and laboratory tests, comments on results and reference to any AEs.

## **10.8. Protocol Deviations**

Protocol deviations will be assessed on a case-by-case basis. Withdrawal of consent for one or more activities within the protocol will not necessarily be considered to be a protocol deviation, and will not necessarily result in the removal of the participant from further study activities. The available data from any such participants will be included in analyses as appropriate. Significant protocol deviations will be reported to the Ethics Committee or IRB according to local regulations.

## **10.9. Access to Source Documentation**

The investigator and staff must agree to allow the study monitor and authorized representatives of the Sponsor to inspect all eCRFs and corresponding source documents, e.g., original medical records, participant records, and laboratory raw data; to have access to the clinical supplies, and dispensing and storage areas; and to agree to assist with their activities if requested. The investigator and staff should provide adequate time and space for monitoring visits.

Participants will have access to safety laboratory results upon request but should be aware that these typically are not immediately available. The results of the baseline biopsy evaluation can be provided to the investigator, who may share them with the participant. Evaluation of the end of treatment renal biopsy, and any other results which might compromise blinding of the study will not be available until after all study analysis is completed.

## 10.10. Data Generation and Analysis

Data generation and analysis will be specified and detailed in the SAP.

## 10.11. Retention of Data

The investigator (or designee) must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents should be classified into at least two separate categories as follows:

- Investigator study file, and
- Participant clinical source documents

The investigator study file will contain the protocol/amendments, CRF and query forms, EC or IRB and governmental approval with correspondence, informed consent, drug records, staff *curricula vitae* and authorization forms, and other appropriate documents and correspondence.

Participant clinical source documents (usually defined by the protocol-specified procedures and data collection requirements in advance to record key efficacy/safety parameters independent of the CRFs) include, but are not limited to, participant hospital/clinic records, physician and nurse notes, appointment book, original laboratory reports, ECG and/or EEG tracings, pathology and special assessment reports, consultant letters, screening and enrollment logs.

All clinical study documents must be retained by the investigator for at least 2 years after the last approval of a marketing application in an ICH region (i.e., United States, Europe, or Japan) and until there are no pending or contemplated marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified. Investigators may be required to retain documents longer if required by applicable regulatory requirements, by local regulations, or by an agreement with Achillion Pharmaceuticals. The investigator (or designee) must contact Achillion Pharmaceuticals prior to destroying any records associated with the study. Achillion Pharmaceuticals will notify the PI when the trial records are no longer needed.

If the investigator withdraws from the study (e.g., relocates, retires, or dies), the records shall be transferred to a mutually agreed upon designee (e.g., another investigator, EC). Notice of such transfer will be given in writing to Achillion Pharmaceuticals. If the investigator cannot guarantee this archiving requirement at the study site for any or all of the documents, special arrangement must be made between the PI and Achillion Pharmaceuticals. to store these in sealed containers outside of the site, so that they can be returned sealed to the PI in case of a regulatory audit. Where source documents are required for the continued care of the participant, appropriate copies should be made for storage outside of the site.

## 10.12. Study and Site Closure

The sponsor reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.



The investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.

Reasons for the early closure of a study site by the sponsor or investigator may include but are not limited to:

- Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
- Inadequate recruitment of participants by the investigator
- Discontinuation of further study intervention development

### **10.13. Final Report, Publication and Disclosure Policy**

All information contained in this protocol and the trial results are considered to be confidential. The investigator agrees to use this information for purposes of conducting this trial. It is understood that Achillion Pharmaceuticals may use data derived from this trial for the purpose of research and development. The data may be disclosed by Achillion Pharmaceuticals to other investigators, the FDA, other government agencies, or foreign drug regulatory authorities, or to the public. No publication of trial design or results is permitted without specific Achillion Pharmaceuticals approval. To gain approval, a copy of the manuscript for review must, therefore, be sent to Achillion Pharmaceuticals 60 days before submission for publication.

It is the intent of Achillion Pharmaceuticals to present the results of this study at future scientific meetings. Additionally, it is the intent of Achillion Pharmaceuticals to publish the results of this study in leading scientific journals. The investigator of each investigative site will be invited to be an author in conjunction with the investigator(s) from Achillion Pharmaceuticals. Achillion Pharmaceuticals will determine additional authors. Presentations and manuscripts will be provided and agreed to by the authors and Achillion Pharmaceuticals.

## 11. REFERENCES

1. PPD [redacted] ACH-0144471 Investigator's Brochure Version 7.0. New Haven (CT): Achillion Pharmaceuticals, Inc.; Aug 2018. 92 p.
2. Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. *Protein Science*. 1996;5(4):553-64.
3. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. *Clinical microbiology reviews*. 1991;4(3):359-95.
4. Miyata T, Inagi R, Oda O, et al. Deterioration of immune complex solubilization activity of serum by increased concentration of factor D. *Nephron*. 1991;59(3):409-15.
5. Kobayakawa H, Miyata T, Inagi R, et al. Effects of excess factor D on early- and late-phase activation of the complement cascade. *Nihon Jinzo Gakkai Shi*. 1992;34(1):103-6.
6. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, et al. C3 Glomerulopathy: clinicopathologic features and predictors of outcome. *Clin J Am Soc Nephrol*. 2014 Jan;9(1):46-53.
7. Servais A, Noël LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. *Kidney Int*. 2012 Aug;82(4):454-64.
8. Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. *Kidney Int*. 2013 Dec;84(6):1079-89.
9. Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. *Clin J Am Soc Nephrol*. 2009 Jan;4(1):22-32. doi: 10.2215/CJN.03480708. Epub 2008 Oct 29.
10. Medjeral-Thomas N, Malik TH, Patel MP, et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. *Kidney Int*. 2014 Apr;85(4):933-7.
11. Lu DF, Moon M, Lanning LD, et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. *Pediatr Nephrol*. 2012 May;27(5):773-81.
12. Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. *J Am Soc Nephrol*. 2007 Sep;18(9):2447-56.
13. Barbour TD, Pickering MC, Cook HT. Dense deposit disease and C3 glomerulopathy. *Semin Nephrol*. 2013 Nov;33(6):493-507

14. De Vriese AS, Sethi S, Van Praet J, et al. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. *J Am Soc Nephrol*. 2015 Dec;26(12):2917-29.
15. Achillion White Paper. The Natural History of C3G. May 5, 2017
16. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. *Nat Genet*. 2002 Aug;31(4):424-8.
17. Abrera Abeleda, Maria Asuncion. The role of the alternative pathway of the complement system in the development of dense deposit disease. University of Iowa, Iowa Research Online, Thesis and Dissertations, 2010.
18. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. *Clin J Am Soc Nephrol*. 2012 May;7(5):748-56.
19. Pickering MC, Warren J, Rose KL, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. *Proc Natl Acad Sci U S A*. 2006 Jun 20;103(25):9649-54.
20. National Organization for Rare Disorders (NORD). 2015. Available at: <https://rarediseases.org/rare-diseases/c3-glomerulopathy-dense-deposit-disease-and-c3-glomerulonephritis/>.
21. Sandhu G, Bansal A, Ranade A, et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. *Am J Kidney Dis*. 2012 Dec;60(6):1039-43. doi: 10.1053/j.ajkd.2012.04.032. Epub 2012 Jul 6.
22. Vernon KA, Goicoechea de Jorge E, Hall AE, et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. *Am J Kidney Dis*. 2012 Jul;60(1):121-5. doi: 10.1053/j.ajkd.2012.02.329. Epub 2012 Apr 13.
23. Fervenza FC, Smith RJ, Sethi S. Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. *Am J Kidney Dis*. 2012 Jul;60(1):126-32. doi: 10.1053/j.ajkd.2012.03.007. Epub 2012 Apr 26.
24. Krmar RT, Holtbäck U, Linné T, et al. Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange. *Clin Nephrol*. 2011 Feb;75 Suppl 1:4-10.
25. Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome

- due to idiopathic membranous nephropathy. *Nephrol Dial Transplant*. 2014 Aug;29(8):1570-7.
26. Stevens LA, Greene T, Levey AS. Surrogate End Points for Clinical Trials of Kidney Disease Progression. *Clin J Am Soc Nephrol*. 2006 Jul;1(4):874-84.
27. Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. *Arthritis Res Ther*. 2015;17(1):110.
28. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. *Arthritis Rheum* 2006 Feb;54(2):421–32.
29. Inker LA, Levey AS, Pandya K, et al, Early Change in Proteinuria as a Surrogate Endpoint for Kidney Disease Progression: An Individual Patient Meta-analysis. *Am J Kidney Dis*. 2014 Jul;64(1):74-85.
30. Lambers Heerspink HJ, Gansevoort RT. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. *Clin J Am Soc Nephrol*. 2015 Jun 5;10(6):1079-88.
31. Inker LA, Mondal H, Greene T, et al. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. *Am J Kidney Dis*. 2016 Sep;68(3):392-401.
32. Thompson A, Cattran DC, Blank M, Nachman PH. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. *J Am Soc Nephrol*. 2015 Dec;26(12):2930-7.
33. Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. *Kidney Int*. 2006 Feb;69(3):504-11.
34. Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. *Am J Med*. 1983 Feb;74(2):175-92.
35. Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study. *Am J Transplant*. 2016 Dec;16(12):3468-78.
36. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. [CTCAE 4.03 June 2010]. Available online at: [http://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm](http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).

## 12. APPENDICES

### Appendix 1. Schedule of Assessments

**Table 4. Schedule of Assessments – Screening through Week 8**

Study Period	Screening <sup>1</sup>		Blinded Treatment									
Study Week			Wk 1			Wk 2	Wk 3	Wk 4	Wk 5	Wk 6	Wk 7	Wk 8
Study Day <sup>2</sup>	Day -75 to Day -1		1	3	7	14	21	28	35	42	49	56
Required Clinic Visit	X	X	X	X	X	X		X		X		X
Phone Visit							X		X		X	
<b>Screening Assessments</b>												
Informed Consent	X											
Inclusion/ Exclusion Criteria	X											
Demographics	X											
Medical History	X		X									
FSH <sup>3</sup>	X											
Urine Drug screen <sup>4</sup>	X											
Vaccinations		X <sup>5</sup>										
Sample for potential genetic assessment of complement genes	X											
<b>Study Drug Dispensing</b>			X			X		X				X
<b>AE/SAE/Protocol Restrictions/Con Meds</b>	X	X	X	X	X	X	X	X	X	X	X	X
<b>Patient-Reported Outcomes Assessments</b>												
FACIT-Fatigue	X											
KDQOL	X											
EQ-5D-3L	X											
<b>Clinical Assessments</b>												
Complete Physical Exam	X		X									
Brief Physical Exam <sup>6</sup>						X						X
Weight	X	X	X <sup>7</sup>	X <sup>7</sup>	X <sup>7</sup>	X <sup>7</sup>		X <sup>7</sup>		X <sup>7</sup>		X <sup>7</sup>
Vital Signs <sup>8</sup>	X	X	X	X	X	X		X		X		X
12-Lead ECG (single)	X		X <sup>7</sup>									
<b>Other Assessments</b>												
Renal Biopsy		X <sup>9</sup>										

**Table 4. Schedule of Assessments – Screening through Week 8 (Continued)**

Study Period	Screening <sup>1</sup>		Blinded Treatment									
Study Week			Wk 1			Wk 2	Wk 3	Wk 4	Wk 5	Wk 6	Wk 7	Wk 8
Study Day <sup>2</sup>	Day -75 to Day -1		1	3	7	14	21	28	35	42	49	56
Required Clinic Visit	X	X	X	X	X	X		X		X		X
Phone Visit							X		X		X	
<b>Standard Laboratory Assessments<sup>10</sup></b>												
Safety Labs: Chemistry <sup>11</sup>	X		X	X	X	X		X				X
Safety Labs: Hematology <sup>11</sup>	X		X	X	X	X		X				X
Serum C3 and C4	X		X <sup>7</sup>			X						
First Morning Urine <sup>12</sup>	X		X <sup>7</sup>			X		X				X
24-Hour Urine Collection <sup>13</sup>		X <sup>13</sup>										
Pregnancy Test <sup>14</sup>	X	X	X			X		X				X
<b>Complement Biomarkers<sup>10</sup></b>	X		X <sup>7</sup>			X						

AE = Adverse event; AP = Alternative pathway; BMI = Body mass index; Con Meds = concomitant medications; ECG = Electrocardiogram; fD = Factor D;  
SAE = Serious adverse event

<sup>1</sup> Screening assessments do not need to all occur on the same day.

<sup>2</sup> Visits should be on the specified day during Weeks 1-3. Starting with the Week 4 visit, visits may be  $\pm$  2 days. Unless the PI feels a clinic visit is required, the visits on Weeks 3, 5 and 7 should be conducted by phone.

<sup>3</sup> FSH for postmenopausal women in screening only.

<sup>4</sup> Urine drug screen should include, at a minimum, amphetamines, barbiturates, cotinine, cocaine metabolites, opiates, benzodiazepines, and cannabinoids.

<sup>5</sup> Patients should be confirmed to be eligible based on all other inclusion and exclusion criteria, except the renal biopsy, before being vaccinated.

<sup>6</sup> Conduct as described in Section 6.7; exam should be prior to dosing. Assessment of edema is part of the brief physical exam. If edema is present, then assessment of edema should be performed at each visit, even when a physical exam is not required.

<sup>7</sup> Prior to dosing.

<sup>8</sup> Vital signs include body temperature, blood pressure in triplicate, heart rate and respiratory rate. Manual measurement of blood pressure is preferred; all other vital signs may be measured using an automated instrument. During the treatment periods, assessments should be collected prior to dosing. Not required for visits conducted by phone.

<sup>9</sup> Renal biopsies should be performed as described in Section 6.3. If obtained during screening to confirm eligibility, the results must be available and reviewed prior to dosing.

<sup>10</sup> During the treatment periods, blood draws and urine collection should be done prior to dosing as detailed in Table 2

<sup>11</sup> As listed in Section 6.11, Table 2.

<sup>12</sup> Should be a first morning void, and will be collected and analyzed as described in Section 6.6.2. Participants should be given a collection container before the visit. If the first morning urine collection coincides with a renal biopsy, collection must be completed before or at least 7 days after the biopsy procedure.

- <sup>13</sup> The 24 hour urine will be collected and analyzed as described in Section 6.6.1. The screening 24-hour urine collection period may be at any time during screening, but if it is to occur after the renal biopsy, it must be at least 7 days after the biopsy procedure.
- <sup>14</sup> Serum pregnancy test at the initial screening visit and urine pregnancy tests at other time points for women of childbearing potential only. On Day 1, urine pregnancy test must be confirmed as negative prior to administration of the first dose of study drug. Any positive urine pregnancy test will be confirmed by a serum pregnancy test. Female participants of childbearing potential must have a urine pregnancy test on the day of any vaccination, and the result must be confirmed as negative prior to vaccine administration.

**Table 5. Schedule of Assessments – Week 10 through Week 28**

Study Period	Blinded Treatment <sup>1</sup>									
Study Week	Wk 10	Wk 12	Wk 14	Wk 16	Wk 18	Wk 20	Wk 22	Wk 24	Wk 26	Wk 28
Study Day	70	84	98	112	126	140	154	168	182	196
Required Clinic Visit		X		X		X				X
Phone Visit	X		X		X		X	X	X	
Study Drug Dispensing		X				X				X
AE/SAE/Protocol Restrictions/Con Meds	X	X	X	X	X	X	X	X	X	X
Patient-Reported Outcomes Assessments										
FACIT-Fatigue										X
KDQOL										X
EQ-5D-3L										X
Clinical Assessments										
Complete Physical Exam <sup>2</sup>										X
Brief Physical Exam <sup>2</sup>		X				X				
Weight		X <sup>3</sup>		X <sup>3</sup>		X <sup>3</sup>				X <sup>3</sup>
Vital Signs <sup>4</sup>		X		X		X				X
Other Assessments										
Renal Biopsy									X <sup>5</sup>	
Standard Laboratory Assessments <sup>6</sup>										
Safety labs: Chemistry		X		X		X				X
Safety labs: Hematology		X		X		X				X
Serum C3 and C4		X								X
First Morning Urine <sup>7</sup>		X				X				X
24-Hour urine collection <sup>8</sup>		X								X
Pregnancy Test <sup>9</sup>		X				X				X
Complement Biomarkers <sup>6</sup>		X								X

AE = Adverse event; AP = Alternative pathway; BMI = Body mass index; Con Med = concomitant medications; fD = Factor D; SAE = Serious adverse event

<sup>1</sup> Visits may take place within a window of  $\pm 2$  days relative to the specified day.

<sup>2</sup> Conduct as described in Section 6.7; during the treatment periods, exam should be prior to dosing. Assessment of edema is part of the brief physical exam. If edema is present, then assessment of edema should be performed at each visit, even when a physical exam is not required.

<sup>3</sup> Prior to dosing.

<sup>4</sup> Vital signs include body temperature, blood pressure in triplicate, heart rate and respiratory rate. Manual measurement of blood pressure is preferred; all other vital signs may be measured using an automated instrument. During the treatment periods, assessments should be done prior to dosing.

<sup>5</sup> The post treatment biopsy should be done prior to the Week 28 dose.



- <sup>6</sup> During the treatment periods, blood draws and urine collection should be done prior to dosing. As listed in Section 6.11, Table 2.
- <sup>7</sup> Should be a first morning void and will be collected and analyzed as described in Section 6.6.2. Participants should be given a collection container before the visit. If the first morning urine collection coincides with a renal biopsy, collection should be completed before or at least 7 days after the biopsy procedure.
- <sup>8</sup> The 24-hour urine will be collected and analyzed as described in Section 6.6.1. The 24-hour urine collection should be within a window of  $\pm$  approximately 1 week relative to the specified day. If the 24-hour urine collection period is to occur after a renal biopsy, it must be at least 7 days after the biopsy procedure.
- <sup>9</sup> Urine pregnancy tests for women of childbearing potential only. Any positive urine pregnancy test will be confirmed by a serum pregnancy test. Pregnancy tests should be done monthly.

**Table 6. Schedule of Assessments – Extended Treatment Period**

Study Period	Extended Treatment <sup>1</sup>							
Study Week	Wk 29	Wk 30	Wk 32	Wk 36	Wk 40	Wk 44	Wk 48	Wk 52
Clinic Visits <sup>1</sup>	X	X		X		X		X
Phone Call			X		X		X	
Study Drug Dispensing		X		X		X		X
AE/SAE/Protocol Restrictions/Con Meds	X	X	X	X	X	X		X
<b>Patient-Reported Outcomes Assessments</b>								
FACIT-Fatigue								X
KDQOL								X
EQ-5D-3L								X
<b>Clinical Assessments</b>								
Complete Physical Exam <sup>2</sup>								X
Brief Physical Exam <sup>2</sup>		X						
Weight	X	X		X		X		X
Vital Signs <sup>3</sup>	X	X		X		X		X
<b>Other Assessments</b>								
Renal Biopsy								X <sup>4</sup>
<b>Standard Laboratory Assessments<sup>5</sup></b>								
Safety labs: Chemistry	X	X		X		X		X
Safety labs: Hematology	X	X		X		X		X
Serum C3 and C4								X
First Morning Urine <sup>6</sup>		X		X				X
24-Hour Urine <sup>7</sup>								X
Pregnancy Test <sup>8</sup>		X		X				X
<b>Complement Biomarkers<sup>5</sup></b>								X

AE = Adverse Event; F/U = Follow-up Visit; QoL = Quality of Life; SAE = Serious Adverse Event

<sup>1</sup> Clinic visits may take place within a window of  $\pm 2$  days relative to the specified day for the Weeks 29-32 and  $\pm 7$  days relative to the specified day for the remainder of the study, except as noted for the Taper, Follow-Up, and Dose Escalation visits. Unless the PI feels a clinic visit is required, the visits on Weeks 32, 40, and 48 may be conducted by phone call. If a patient is unable to get to a clinic visit during the COVID-19 global pandemic (Section 6.22), study data collection should still occur. The preferred option is **home healthcare visits**; nurses may collect 24-hour urine, first morning urine, and safety labs, including pregnancy testing. Additional assessments should include AEs, vital signs, and concomitant medications. Nurses will perform study drug accountability. If a home healthcare visit is not possible, patients may have **telephone visits** with the PI or designee. Data collection will include AEs and concomitant medications, and patients will be asked about study drug compliance.

- <sup>2</sup> Conduct as described in Section 6.7; during the treatment periods, exam should be prior to dosing. Assessment of edema is part of the brief physical exam. If edema is present, then assessment of edema should be performed at each visit, even when a physical exam is not required.
- <sup>3</sup> Vital signs include body temperature, blood pressure in triplicate, heart rate and respiratory rate; manual measurement of blood pressure is preferred. All other vital signs may be measured using an automated instrument. During the treatment periods, assessments should be done prior to dosing.
- <sup>4</sup> As part of the Biopsy sub-study, a renal biopsy may be obtained at approximately Week 52, if not contraindicated. If clinic visits are not possible during the COVID-19 global pandemic, the Week 52 biopsy should be done when safe to do so, even if the biopsy is unable to be done within 7 days of the target date. In addition, an unscheduled 24-hour urine collection should be obtained at the same time as the Week 52 renal biopsy (Section 6.24). If the collection of 24-hour urine is to occur after a renal biopsy, it must be done at least 7 days after the biopsy procedure.
- <sup>5</sup> During the treatment periods, blood draws and urine collection should be done prior to dosing, as detailed in Section 6.11, Table 2. Blood collection for biomarkers will not be done at home health visits or at local laboratories. If a home visit occurs but laboratory samples cannot be shipped to the central laboratory by the nurse conducting home visits, the nurse should go to a local laboratory to drop off all laboratory samples, including 24-hour urine collections and safety labs. If home visits are not possible, the participant should go to a local laboratory to drop off 24-hour urine collections and for safety laboratory testing, including pregnancy testing (if applicable), to be performed.
- <sup>6</sup> Should be a first morning void, and will be collected and analyzed as described in Section 6.6.2. Participants should be given a collection container before the visit. If the first morning urine collection coincides with a renal biopsy, collection should be completed before or at least 7 days after the biopsy procedure.
- <sup>7</sup> The 24-hour urine will be collected and analyzed as described in Section 6.6.1. The 24-hour urine collection should be within a window of  $\pm$  approximately 1 week relative to the specified day. If the 24-hour urine collection period is to occur after a renal biopsy, it must be at least 7 days after the biopsy procedure. If a clinic visit is not possible and a home healthcare visit is done, the home healthcare nurse will collect the 24-hour urine sample. If a telephone visit is done instead, the patient should take the 24-hour urine to the local laboratory, if possible.
- <sup>8</sup> Urine pregnancy tests for women of childbearing potential only. Any positive urine pregnancy test will be confirmed by a serum pregnancy test. Pregnancy tests should be done monthly.

**Table 7. Schedule of Assessments – 21 Month Long-Term Follow-up, with Taper and Follow-up**

Study Period	Long-Term Follow-up				Taper <sup>2</sup>		Follow-up <sup>3</sup>	
Study Week	Wk 65 Wk 117	Wk 78 Wk 130	Wk 91 Wk 143	Wk 104	T3	T6	F/U 1	F/U 2
Clinic Visits <sup>1</sup>	X	X	X	X	X		X	
Phone Call						X		X
Study Drug Dispensing	X	X	X	X	X			
AE/SAE/Protocol Restrictions/Con Meds	X	X	X	X	X	X	X	X
<b>Patient-Reported Outcomes Assessments</b>								
FACIT-Fatigue				X			X	
KDQOL				X			X	
EQ-5D-3L				X			X	
<b>Clinical Assessments</b>								
Complete Physical Exam <sup>4</sup>				X				
Brief Physical Exam <sup>4</sup>		X			X		X	
Weight	X	X	X	X	X		X	
Vital Signs <sup>5</sup>	X	X	X	X	X		X	
<b>Histology</b>								
Renal Biopsy				X <sup>6</sup>				
<b>Standard Laboratory Assessments<sup>7</sup></b>								
Safety labs: Chemistry	X	X	X	X	X		X	
Safety labs: Hematology	X	X	X	X	X		X	
Serum C3 and C4		X		X	X		X	
First Morning Urine <sup>8</sup>		X		X	X		X	
24-Hour Urine <sup>9</sup>				X				
Pregnancy Test <sup>10</sup>		X		X			X	
<b>Complement Biomarkers<sup>7</sup></b>		X		X	X		X	

AE = Adverse Event; F/U = Follow-up Visit; QoL = Quality of Life; SAE = Serious Adverse Event; T3 = Day 3 of the taper; T6 = Day 6 of the taper; Wk = Weeks

<sup>1</sup> Clinic visits may take place within a window of  $\pm 2$  days relative to the specified day for the Weeks 29-32 and  $\pm 7$  days relative to the specified day for the remainder of the study, except as noted for the Taper, Follow-Up, and Dose Escalation visits. If a patient is unable to get to a clinic visit during the COVID-19 global pandemic (Section 6.22), study data collection should still occur. The preferred option is **home healthcare visits**; nurses may collect 24-hour urine, first morning urine, and safety labs, including pregnancy testing. Additional assessments should include AEs, vital signs, and concomitant medications. Nurses will perform study drug accountability. If a home healthcare visit is not possible, patients may have **telephone visits** with the PI or designee. Data collection will include AEs and concomitant medications, and patients will be asked about study drug compliance.

- <sup>2</sup> Participants should gradually decrease the daily total dose of ACH-0144471 during the taper. Visits should be on the 3<sup>rd</sup> (T3) and 6<sup>th</sup> (T6) day of the taper.
- <sup>3</sup> Follow-up visits should be conducted 2 and 4 weeks after the last dose of ACH-0144471 (including the taper, if applicable), within a window of  $\pm 2$  days.
- <sup>4</sup> Conduct as described in Section 6.7 ; during the treatment periods, exam should be prior to dosing. Assessment of edema is part of the brief physical exam. If edema is present, then assessment of edema should be performed at each visit, even when a physical exam is not required.
- <sup>5</sup> Vital signs include body temperature, blood pressure in triplicate, heart rate and respiratory rate; manual measurement of blood pressure is preferred. All other vital signs may be measured using an automated instrument. During the treatment periods, assessments should be done prior to dosing.
- <sup>6</sup> As part of the Biopsy sub-study, a renal biopsy may be obtained at approximately Week 104, if not contraindicated. If clinic visits are not possible during the COVID-19 global pandemic, the optional Week 104 biopsy should be done when safe to do so, even if the biopsy is unable to be done within 7 days of the target date. In addition, an unscheduled 24-hour urine collection should be obtained at the same time as the Week 104 renal biopsy (Section 6.24). If the collection of 24-hour urine is to occur after a renal biopsy, it must be done at least 7 days after the biopsy procedure.
- <sup>7</sup> During the treatment periods, blood draws and urine collection should be done prior to dosing, as detailed in Section 6.11, Table 2. Blood collection for biomarkers will not be done at home health visits or at local labs. If a home visit occurs but laboratory samples cannot be shipped to the central laboratory by the nurse conducting home visits, the nurse should go to a local laboratory to drop off all laboratory samples, including 24-hour urine collections and safety labs. If home visits are not possible, the participant should go to a local laboratory to drop off 24-hour urine collections and for safety laboratory testing, including pregnancy testing (if applicable), to be performed.
- <sup>8</sup> Should be a first morning void, and will be collected and analyzed as described in Section 6.6.2. Participants should be given a collection container before the visit. If the first morning urine collection coincides with a renal biopsy, collection should be completed before or at least 7 days after the biopsy procedure.
- <sup>9</sup> The 24-hour urine will be collected and analyzed as described in Section 6.6.1. The 24-hour urine collection should be within a window of  $\pm$  approximately 1 week relative to the specified day. If the 24-hour urine collection period is to occur after a renal biopsy, it must be at least 7 days after the biopsy procedure.
- <sup>10</sup> Urine pregnancy tests for women of childbearing potential only. Any positive urine pregnancy test will be confirmed by a serum pregnancy test. Pregnancy tests should be done monthly.

## **Appendix 2. Fever Management Plan**

Treatment with complement inhibitors may lead to an increased lifetime risk of acute meningococcal disease, or other encapsulated bacterial infection. Because of this risk, it is essential to monitor participants for signs and symptoms of infection.

### **Minimum Requirements**

The points mentioned below are to be considered as a minimum diagnostic and management procedure. These are not meant to replace or bypass a systematic and thorough assessment of the participant; instead, they are intended to facilitate rapid initiation of assessment and management of fever.

### **General Management for Any Fever Detected in the Clinic**

For any fever, the site must:

1. Assess for symptoms - consider meningococcal disease as a diagnosis. When meningococcal disease is suspected, early treatment is critical
2. Repeat and confirm all temperature measurements  $>38.0^{\circ}\text{C}$
3. Notify the PI and Sponsor for all confirmed temperature measurements  $>38.0^{\circ}\text{C}$
4. Consider if referring to an emergency medical facility is appropriate. If so, refer. Otherwise:
  - a. PI or designee to perform a complete physical examination (including assessing if fever is accompanied by a severe headache, stiff neck, or other signs of meningeal irritation, shortness of breath, skin rashes, or other unusual signs or symptoms), document a plan based on her/his clinical judgment, and possibly an ID consult depending on assessment
  - b. CBC (if not done in the last 12 hours) and blood culture
  - c. Treat any suspicion of meningococcal infection aggressively; consider initiation of empirical antimicrobial therapy (assuming there are no other obvious sources of fever) at least until culture results become available and/or an alternative etiology is found
  - d. Infectious disease consult is required once the PI or designee initiates empiric antibiotic treatment
  - e. Measure temperature hourly until  $<38.0^{\circ}\text{C}$
  - f. All cases of fever will be assessed by the Investigator, regardless of apparent causality from use of the study treatment(s)
  - g. All activities performed as part of the Fever Management Plan should be documented

### **Acute Meningococcal Disease**

If acute meningococcal disease is diagnosed, immediate medical and antibiotic management by local physician must be initiated documented and reported to the sponsor's medical monitor immediately, but not more than 24 hours from diagnosis.

Normal body temperature varies over the course of the day. The normal daily temperature variation is typically  $0.5^{\circ}\text{C}$  ( $0.9^{\circ}\text{F}$ ). During a febrile illness, daily low and high temperature

readings are maintained but at higher levels. However, this daily variation can be as high as 1.0°C in some individuals recovering from a febrile illness.